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Summary
Neuroendocrine (NE) cells are found in a majority of the body organs. In the 
gastrointestinal (GI) tract, enterochromaffin cells (EC) constitute the largest NE cell 
population and they are distributed from the cardia to the anus. The EC cell population 
includes several different sub-populations, and morphological differences in shape, 
luminal endings and secretory granules suggest region-specific functions. The main 
secretory product of EC cells is serotonin and EC cells account for more than 90 % of 
all serotonin synthesized in the body. Serotonin is thought to be released from the EC 
cell by degranulation at the base of the cell as a response to luminal stimuli acting on 
the apical part of the cell. Serotonin functions as a key regulator of regional blood flow, 
motility and secretion in the gut. The embryological origin of EC cells is still under 
debate. Many researchers today believe that EC cells are derived from a local mucosal 
stem cell. In paper (I) we described a new method for visualizing morphologically intact 
mucosal EC cells. Some EC cells made contact with mucosal cells via axon-like, 
infranuclear cytoplasmatic extensions, while others had extensions that connected with 
underlying neurons. A third EC cell type had no or only short and blunt extensions. The 
serotonin released from these EC cells may reach targets such as neighboring cells or 
fenestrated capillaries through diffusion. EC cells were found to have striking 
morphological similarities with serotonergic neurons, thus indicating that they are 
derived from the neural crest. The finding of EC cells in mitosis, also makes the local 
mucosal stem cell theory less plausible.  
Carcinoid tumors arising from the EC cell produce large amounts of serotonin 
and other hormonally active substances, giving rise to the carcinoid syndrome. The 
major features of the carcinoid syndrome are flushing, diarrhea, asthma and the 
carcinoid heart disease. Carcinoid heart disease occurs in more than 65 % of patients 
with the carcinoid syndrome and is characterized by fibrous thickening of cardiac 
valves, leading to heart failure. Whether serotonin is directly responsible for these 
cardiac abnormalities has so far been unknown. In order to address this issue we 
injected rats with high doses of serotonin once daily for three months (II). For the first 
time we could show that serotonin administration leads to a carcinoid heart-like 
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condition in rats, thus proving the relationship between serotonin and heart valve 
disease.
Serotonin is a well-known mitogen with proliferative effects on different cells of 
mesenchymal origin as well as macrophages via specific serotonin receptors. Two key 
cell types involved in bone metabolism are the mesenchymally derived bone forming 
osteoblasts and the bone-resorbing osteoclasts derived from the monocyte/macrophage 
lineage. It was recently shown that osteoblasts and osteoclasts have functional serotonin 
receptors. In paper (III) we performed in vitro experiments demonstrating that serotonin 
induces proliferation of human bone marrow stem cells, human osteoblasts and murine 
preosteoblasts. Serotonin also increased osteoclast differentiation and activity. This 
effect, however, seemed to be opposed by the finding that serotonin induced an increase 
in the OPG/RANKL ratio in osteoblast cell culture medium, indicating an inhibitory 
effect on bone resorption. A regulatory function for serotonin in bone became even 
more likely when we found that osteoblasts and osteoclasts expressed tryptophan 
hydroxylase 1 (Tph 1), the rate-limiting enzyme in serotonin synthesis, indicating that 
they are able to produce serotonin. We also investigated the effects of the selective 
serotonin reuptake inhibitor (SSRI) fluoxetine on bone metabolism in vitro. Fluoxetine 
inhibited osteoblast proliferation and reduced the OPG/RANKL ratio, indicating an 
overall negative effect on bone metabolism. These results may be of clinical importance 
as fluoxetine is the most used antidepressant drug worldwide. To evaluate possible 
effects of serotonin on bone formation in vivo, a long-term study with daily, low dose 
serotonin injections was performed in growing rats (IV). After three months, a 
significant increase in bone mineral density (BMD) developed. Micro-computed 
tomography (ȝCT) scans were performed to study bone architecture. In the serotonin 
group, the femoral cortex was thicker, whereas the trabecular bone volume was lower 
compared to controls, indicating a decrease in bone resorption or/and increased 
apposition of endosteal bone. These data were in accordance with the fact that the 
serotonin dosed animals had stiffer bones in mechanical tests. The in vivo findings may 
be explained by the serotonin-induced increase in proliferation of osteoblastic cells and 
elevated OPG/RANKL ratio induced by serotonin in vitro.
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Introduction
1.1 Endocrine cells of the gut 
In 1902, Bayliss and Starling were the first to introduce the concept that chemical 
messengers (hormones) played an important role in the control of physiologic functions 
(1). It is now well established that normal secretory, absorptive and motor functions of 
the GI tract are controlled by a complex combination of regulatory mechanisms that are 
chemically mediated. These so-called regulatory chemical messengers (gut hormones 
and neurotransmitters) are usually either biogenic amines or polypeptides, and are 
normally present in the nerve terminals of the myenteric plexuses and in endocrine cells 
dispersed within the mucosal lining of the gut. Endocrine cells within the gut epithelium 
from the stomach to the rectum represent the largest population of hormone producing 
cells in the body (2). They are scattered as individual cells throughout the mucosa, 
comprising approximately 1 % of the cells lining the GI lumen. 
Feyrter was the first to describe the “diffuse neuroendocrine cell system” in 
1938 (3). During the 1960s, gastrointestinal endocrine cells were found to express 
markers for neuronal differentiation, including those involved in the biosynthesis of 
neurotransmitters, as well as showing ultrastructural properties common to those of 
neurons. In 1969, Pearse described the amine precursor uptake and decarboxylation 
properties of NE cells and introduced the APUD concept, and he also proposed that 
APUD cells stemmed from the neural crest (4). The resemblance between gut endocrine 
cells and nerve cells gave birth to the “paraneuron” concept (5). The microvilli were 
regarded as the sensory part of the nerve cell, the cell body as the signal transport 
portion and the exocytosed secretory granules as the message. The hypothesis that NE 
cells are of neural crest origin has been opposed by others, and using embryonic cell 
tracing techniques they conclude that NE cells are derived from a common endodermal 
stem cell (6-8). 
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1.2 The enterochromaffin (EC) cell 
In 1870 Heidenhain described the chromaffin (from their ability to stain a brownish 
color with chromic salts) cells in the gut (9). Later Kultschitzky described them as 
basigranular acidophil cells and as a result the cells were named Kultschitzky cells (10). 
The term enterochromaffin cell was first used by Ciaccio in 1907 (11). The functional 
significance of these cells remained obscure until Masson observed their affinity for 
silver salts (argentaffinity) and suggested that they probably served an endocrine 
function (12). 
 EC cells are distributed all along the gastrointestinal tract, from the cardia to the anus. 
They comprise the major population of gut endocrine cells and play a pivotal role in 
several aspects of gut function including secretion, motility and sensation (13, 14). EC 
cells synthesize, store and release the biogenic amine serotonin (5-hydroxytryptamine 
(5-HT)) as well as a variety of peptides (15-19). The biochemical pathway for serotonin 
synthesis initially involves the conversion of the essential amino acid tryptophan to 5-
hydroxytryptophan by the enzyme tryptophan hydroxylase (Tph). This enzyme provides 
the rate limiting step for serotonin synthesis. The subsequent metabolic step in the 
synthesis of serotonin involves the decarboxylation of 5-hydroxytryptophan into 5-
hydroxytryptamine by the action of the enzyme 5-hydroxytryptophan decarboxylase. 
EC cells accumulate serotonin in secretory vesicles via vesicular monoamine transporter 
1 (VMAT-1) (20). In the secretory vesicles, serotonin is colocalized with 
chromogranins, which are acidic proteins with diverse functions such as amine storage 
proteins and pro-hormones in enteroendocrine cells (21-24). Most EC cells are of the 
“open” type with apical cytoplasmatic extensions which project into the glandular 
lumen with short microvilli (Fig. 1). These structures represent the anatomical basis for 
the cell response to physical or chemical variations in luminal content (25). EC cells 
have been referred to as “taste buds of the gut” and are believed to function as sensory 
transducers that activate mucosal processes of both intrinsic and extrinsic primary 
afferent neurons through their release of serotonin from granule stores located at the 
base of the cells (14, 26). Secreted serotonin may also influence adjacent cells by 
paracrine actions and exert hormonal effect on distant cells via the blood circulation. EC 
10
cells with cytoplasmatic processes sometimes projecting into adjacent glands have been 
shown, suggesting a role for EC cells in functional synchronization of neighboring 
glands (27, 28). After release, most of the serotonin is rapidly transported by the cell 
membrane-bound serotonin transporter (5-HTT) into a number of cell types, with 
platelets serving as a reservoir. It has been estimated that the adult human body has 
about 5 to 10 mg of serotonin, 90 % of which are in the intestine and the rest in blood 
platelets and the brain. The free circulating fraction of serotonin is very low due to a 
rapid degradation to 5-hydroxyindoleacetic acid (5-HIAA) by monoamine oxidase in 
the liver and lungs.   
Figure 1.   Left, diagram illustrating the hypothesis regarding initiation of the peristaltic reflex. A 
bolus in the intestinal lumen exerts pressure on the mucosa that causes serotonin to be 
secreted from enterochromaffin (EC) cells. The serotonin enters the lamina propria, where it 
reaches serotonin receptors on the terminals of submucosal sensory neurons. Serotonin thus 
participates in the initiation of the peristaltic reflex. Right, diagram showing how a luminal 
stimulus acts on EC cell microvilli, leading to degranulation of infra-nuclear stores of serotonin 
(illustration by Sarah Bååth Krantz). 
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From a historical perspective a number of histochemical techniques have been 
used to visualize EC cells (29, 30). Nowadays immunohistochemical staining 
techniques using antibodies specifically directed against serotonin represent a very 
convenient, reproducible and specific method for the visualization and identification of 
EC cells. 
1.3 The carcinoid syndrome 
Carcinoid tumors were first described by Lubarsch in 1888, when he reported the 
autopsy findings of two patients with multiple tumors in the distal ileum (31). The term 
carcinoid was introduced in the literature by Oberndorfer in 1907 in his description of a 
class of malignant tumors that behaved less aggressively than the more common 
adenocarcinomas of the GI tract (32). The exact nature of the tumor was not determined 
until 1928 when Masson described its origin as the enterochromaffin cell (33). A 
syndrome associated with these neoplasms was independently reported by Isler and 
Rosenbaum in 1953 and Thorson in 1954 (34-36). The carcinoid syndrome is caused by 
biologically active tumor products, such as serotonin, dopamine, cathecholamines, 
bradykinin and tachykinins (37-40). The primary tumor, most often located in the ileum, 
rarely gives any symptoms. If metastases to the liver occur, however, the tumor 
products drain into the caval system via the hepatic veins, thus bypassing inactivation 
by the liver. The result is that large amounts of tumor products enter the blood 
circulation and the carcinoid syndrome develops, typically consisting of episodic skin 
flushing, diarrhea, bronchoconstriction, sweating, abdominal cramping, and valvular 
heart disease. 
1.4 Carcinoid heart disease 
Carcinoid heart disease describes cardiac and vascular changes associated with the 
carcinoid syndrome. Fibrous plaques on the endocardial surface of the valvular cusps 
and the cardiac chambers, and on the intima of the great veins and arteries occur. The 
plaques contain deposits of myofibroblasts, fibroblasts, and smooth muscle cells in a 
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myxoid matrix (41). Carcinoid plaques are seen in areas subjected to the greatest 
concentrations of tumor products (42, 43). The cause of carcinoid heart disease is 
unknown, but serotonin was early mentioned as a possible agent involved in the 
pathogenesis (44). Among patients with the carcinoid syndrome, those with the highest 
levels of tachykinin and serotonin in serum and 5-HIAA in the urine are prone to 
develop heart valve changes (45-48). In addition to its role as a regulator of secretive 
processes, serotonin has been found to modulate cell proliferation in fibroblasts, 
valvular subendocardial cells and other cells of mesenchymal origin (49-53). 
 Serotonin produces its effects through a variety of membrane-bound receptors 
(54). With the exception of the 5-HT3 receptor, which is a ligand-gated ion channel, 5-
HT receptors belong to the G-protein-coupled receptor (GPCR) super family and, with 
at least 14 distinct members, represent one of the most complex families of 
neurotransmitter receptors. Human heart valves have been shown to express mRNA for 
the 5-HT1B, 1D, 2A and 2B receptors (55, 56). Fenfluramine, a serotonergic drug used as an 
appetite suppressant, was withdrawn from the market in 1997 because it induced a 
valvular heart disease similar to that seen in the carcinoid syndrome (57). This effect 
may be mediated via the 5-HT2B receptor (56, 58).  It has also been shown that ablation 
of the 5-HT2B receptors in mice leads to abnormal cardiac development with hypoplastic 
ventricles (59). On the other hand, the 5-HT2A receptor seems to be involved in 
upregulation of transforming growth factor-ȕ and stimulation of glycosaminoglycan 
production in sheep aortic interstitial cells (60). In conclusion, several in vitro studies 
point out serotonin as the major pathogen in carcinoid heart disease, in vivo however, 
this has not been verified. 
1.4 The skeleton 
Bone is a specialized connective tissue that makes up, together with cartilage, the 
skeletal system. These tissues serve three main functions: 1. mechanical: support and 
site of muscle attachment for locomotion, 2. protective: for vital organs and bone 
marrow; and 3. metabolic: as a reserve of ions, especially calcium and phosphate. 
Anatomically, two types of bones exist in the skeleton: flat bones (skull bones, scapula, 
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mandible and ileum), and long bones (tibia, femur and humerus). The skeleton is 
composed of an outer layer of compact or cortical bone with low porosity and the inner 
trabecular (cancellous) with high porosity (Fig. 2 and 3). The skeleton consists of 
approximately 80 % cortical bone, largely in peripheral bones, and 20 % trabecular 
bone, mainly in the axial skeleton.  
The diverse functions of bone are reflected in its composition. Bone tissue is 
composed of an extracellular matrix (largely mineralized), collagen and cells 
responsible for the formation and maintenance of the bone matrix.  The cells of the bone 
maintain the structure of the skeleton and adapt it to mechanical demands placed upon 
it. Powerful systems organize and control the numbers, location, and work efficiency of 
cells involved in bone metabolism.  
Figure 2. A human long bone 
(femur) (illustration by Sofie 
Gustafsson). 
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Figure 3. Structure of trabecular bone (with permission from professor Philip Sambrook, 
University of Sydney). 
1.6 Bone cell function, modeling and remodeling
While trabecular bone accounts for the minority of total skeleton tissue, it is the site of 
higher bone turnover because its total surface is greater than that of cortical bone. In a 
growing individual bone continuously changes its shape, structure, and mass by two 
types of bone formation, endochondral and periosteal apposition, determining the length 
and width of the bones (61). During this process called modeling, the bone formation 
exceeds bone resorption. In adulthood the process of bone remodeling maintains the 
mechanical integrity of the skeleton. Remodeling is a strict coupling of bone resorption 
and formation. This process continues throughout life, in order to replace damaged bone 
with new bone (62-64). If this balance of bone formation and resorption is disturbed 
(un-coupled), pathological states with loss of bone like osteoporosis or with increased 
bone mass like osteopetrosis, may develop (65-67).  
The process of bone remodeling involves three different cell types that can 
respond to various environmental signals. The osteoblast is situated on the bone surface 
at sites of active bone matrix formation (Fig. 4). It originates from a local mesenchymal 
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stem cell and in cell culture, osteoblasts are nearly indistinguishable from fibroblasts 
(68-70). Osteoblasts produce bone matrix proteins including type I collagen, the most 
abundant extracellular bone protein, and also takes charge of mineralization of the 
tissue. Other cells in the osteoblastic lineage are the osteoblast precursor cells (pre-
osteoblasts), bone lining cells, and osteocytes. Pre-osteoblasts are located near bone 
formation sites, and can rapidly develop into mature osteoblasts. In adult bone some 
surfaces are not actively involved in bone formation or resorption. These surfaces are 
covered with a thin layer of flattened cells, the bone lining cells. Bone lining cells are 
formed from osteoblasts when bone formation stops, but are thought to have the ability 
to re-differentiate into active osteoblasts when needed (71). Osteocytes are considered 
to be osteoblasts that were trapped in the bone matrix that they produced. They possess 
several long extensions that can contact other osteocytes, osteoblasts, lining cells or/and 
osteoclasts and their precursors. It has been suggested that osteocytes sense mechanical 
load to bone, and thus participate in the modulation of bone (72, 73). 
 Osteoclasts are multinucleated, bone resorbing cells originating from 
hematopoetic mononuclear cells (74). They are usually found in contact with a calcified 
bone surface and within a lacuna (Howship`s lacunae) that is the result of its own 
resorptive activity. Bone remodeling follows an ordered sequence. In this cycle, bone 
resorption is initiated by recruitment of osteoclasts. Osteoclasts have a membrane called 
the ruffled border through which hydrochloric acid and lysosomal enzymes are released, 
causing bone resorption. This resorptive phase is followed by a bone formation phase 
where osteoblasts fill the lacunae produced by osteoclasts with osteoid, which is 
subsequently mineralized to form new bone matrix. 
 The functions of osteoblasts and osteoclasts are closely linked. Cells from the 
osteoblast lineage synthesize and secrete molecules that initiate and control osteoclast 
differentiation. It is known that two hematopoetic factors are crucial for 
osteoclastogenesis, the polypeptide growth factor M-CSF-1 (Macrophage-Colony 
Stimulating Factor-1) and Receptor Activator of NF NB Ligand (RANKL), a member of 
the TNF super-family. Both are expressed by osteoblasts and their immature precursors 
(75, 76). RANKL activates its receptor, RANK, which is expressed on osteoclasts and 
their precursors. Thus, RANKL promotes osteoclast formation and activation and 
prolongs osteoclast survival by suppressing apoptosis (77).   
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Figure 4. Diagram showing the different cell types involved in bone remodeling 
(illustration by Sarah Bååth Kranz). 
Osteoprotegerin (OPG) is a secretory glycoprotein that is also expressed by the 
osteoblast and its precursors. It inhibits osteoclast differentiation and activation by 
binding to RANKL and preventing it from activating RANK (78). The balance between 
RANKL and OPG is regulated by multiple factors including cytokines, growth factors, 
systemic hormones and transcriptional factors, which together determines the overall 
osteoclast function (79-81).
Recently, signaling molecules present in the peripheral nervous system and 
mechanisms controlled by the central nervous system, have been shown to be involved 
in the regulation of bone metabolism (82-84). Studies on nerve terminals in bone have 
demonstrated the presence of several neuropeptides (85). In the 1990s, Rahman et al.
showed effects of bradykinin and vasoactive intestinal peptide (VIP) on bone cell 
activity in vitro (86, 87). A few years later two groups, almost simultaneously, 
discovered that glutamate could act as a signaling molecule in bone, and it is now 
recognized that both osteoclasts and osteoblasts can be regulated by glutamate (88-92). 
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Receptors for the neuropeptides VIP and pituitary adenylate cyclase-activating 
polypeptide (PACAP) have been demonstrated on both osteoblasts and osteoclasts and 
activation of these receptors causes profound changes in the activity of the cells (93, 
94). It has also been shown that leptin is expressed in and secreted from primary 
cultures of human osteoblasts and promotes bone mineralization, (95) and recently it 
was demonstrated that ghrelin stimulates bone formation (96). In 2000, functional 
serotonin receptors in both osteoblasts and osteocytes were demonstrated (97). 
Furthermore, 5-HTT was demonstrated in rat osteoblasts (98).
1.7 Biomechanics of bone
The strength of bone and its ability to resist fracture is dependent on its mass and 
geometry, but also on intrinsic (material) properties of the bone tissue itself (99). The 
mineral content provides strength and stiffness to the tissue, but at increasing levels of 
mineralization, the tissue can become more brittle, reducing the energy required for 
fracture (100, 101). The collagen matrix also contributes to a large extent to the 
mechanical properties of bone (101). It has been shown that changes in collagen 
structure contribute to the age-associated reduction in bone toughness and an increased 
fracture risk independent of BMD (102). Bone fragility can be defined as the 
susceptibility to fracture. The biomechanical definition of bone fragility include at least 
three components: strength, brittleness and work to failure. A fourth measure, stiffness, 
is also used to assess mechanical integrity of bones. When a force (load) in a known 
direction is placed on a structure, the displacement (deformation) of the structure can be 
measured and plotted on a force-displacement curve (Fig. 5A). Bone strength (ultimate 
force) is defined as the height of the curve, and describes the maximum force the bone 
can sustain before it breaks. The energy it can store before fracture, or work to failure, is 
the area under the curve. 
 Skeletal disease can cause fragile bones by affecting bone structure in different 
ways. Osteopetrosis, with an increased bone mass, causes stiff, brittle bones (Fig. 5B). 
They absorb very little energy before breaking (reduced work to failure) and are 
therefore more susceptible to fracture resulting from trauma. In osteomalacia with a 
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deficiency of vitamine D and calcium, the bone tissue becomes soft, which also leads to 
reduced work to failure. These bones, however, can deform considerably before 
breaking. An ideal drug to cure bone fragility would improve strength and decrease 
brittleness (Fig. 5C). 
Figure 5. Diagrams showing force-displacement curves. A; the height of the curve represents 
the strength, the area under the curve is the work to failure (U), the maximum slope of the curve 
is the stiffness (S) and the width of the curve is the ultimate displacement (reciprocal of 
brittleness). B; osteopetrosis reduces the displacement before failure and thus increases 
brittleness. Osteomalacia decreases brittleness but reduces the force at failure and thus 
weakens bone. C; an ideal treatment for bone fragility. 
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Aims of the studies 
1. To develop a new technique for visualization of morphologically intact gut mucosal 
cells.
2. To study the morphology of the enterochromaffin cell in different parts of the rat 
gastrointestinal tract. 
3. To examine the expression of serotonin receptors in rat aortic valves. 
4. To create a carcinoid syndrome-like condition in rats and investigate whether heart 
valve changes similar to those seen in the carcinoid heart disease appear. 
a. By echocardiography. 
b. By histological and immunohistological examinations. 
5. To describe the effects of serotonin and the selective serotonin reuptake inhibitor 
fluoxetine on bone metabolism in vitro.
a. By investigating the effects of serotonin and/or fluoxetine on proliferation of 
human and murine osteoblastic cells in vitro.
b. By investigating the effects of serotonin and/or fluoxetine on proliferation, 
differentiation and activity of human and murine osteoclastic cells in vitro.
c. By examining the expression of serotonin receptors and the serotonin transporter 
in human osteoclasts, and the rate limiting enzyme in serotonin synthesis (Tph) 
in osteoblasts and osteoclasts in vitro.
d. By examining the release of factors modulating bone metabolism from 
osteoblasts treated with serotonin and/or fluoxetine in vitro.
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6. To study the consequences on bone of long-term administration of serotonin to 
growing rats. 
a. By measuring the bone mineral density with DXA. 
b. By examining the femurs with micro-computed tomography. 
c. By studying the histology of bones with histomorphometry. 
e. By performing mechanical testing on femurs. 
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Methodological considerations 
The details of all procedures have been described in each paper and only general 
comments concerning the different methods will be given. 
1.1 Dispersion of formalin-fixed gut mucosal cells 
Dispersion of tissues is done to obtain a single-cell suspension with all the different cell 
types composing the tissue. Traditionally, dispersion of gut mucosa cells has been done 
using a fresh and unfixed organ. To disperse mucosal cells from the stomach or the 
intestinal wall, a combination of proteolytic enzymes, acalcemia and mechanical force 
is needed (103-105). What is unique about the method used in paper I is that the 
different parts of the GI tract were fixed in formalin before dispersion, which results in 
morphologically intact cells in the cell suspension. To accomplish the dispersion of 
mucosal cells from formalin-fixed tissue we created a modified method based on the 
principals of enzymatic, chemical and mechanical detachment, and segregation of cells.  
1.2 Immunohistochemical staining 
Immunohistochemistry is a method using specific antibodies to detect molecules in their 
in situ localization on a tissue slide or in cell smears. The principle of 
immunohistochemistry has been known since the 1930s, but it was not until 1941 that 
the first immunohistochemistry study was reported (106). All stainings used in this 
thesis were done by the EnVision-system (DAKO, Glostrup, Denmark). The EnVision-
system is based on dextran polymer technology. This chemistry permits binding of a 
large number of enzyme molecules (horseradish peroxidase or alkaline phosphatase) to 
a secondary antibody via the dextran backbone. The benefits are many, including 
increased sensitivity, minimized non-specific background staining and a reduction in the 
total number of assay steps as compared to conventional techniques. In brief, the 
protocol was as follows; i) Application of primary antibody; ii) Application of enzyme 
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labeled polymer; iii) Application of the substrate chromogen. In paper I, specific 
antibodies directed against serotonin were used, whereas antibodies directed against Ki-
67 were used in paper II. The antigen Ki-67 is a ubiquitous nuclear protein expressed in 
G1-, S-, and G2-phases of the cell cycle, but not in the G0-phase, and is therefore a
measure of the growth fraction of cells (107-109).  
1.3 Animal studies 
All animals used were female Sprague Dawley rats. The reason for working only with 
female rats was that I had developed a rat allergy. The allergens produced by rats are 
well characterized, and it is believed that the urine of adult male rats is the most 
important source of allergen (110). In paper I, the animals were sacrificed without any 
prior treatment or procedures. Paper II and IV were in vivo studies to investigate the 
biological effects caused by long-term administration of serotonin (5-
Hydroxytryptamine Creatinin Sulfate Complex, Sigma-Aldrich). Serotonin is well 
recognized as an unstable compound and decomposes quickly if treated improperly. 
Temperature, pH, and some metal ions are known to affect its degradation. As serotonin
can not be administered orally, we first performed long-term infusion with serotonin 
using mini pumps. However, due to degradation of serotonin in the pumps, no 
detectable increase in plasma serotonin occurred (unpublished observation). The 
problem was overcome by daily subcutaneous injections of freshly dissolved serotonin.
1.4 Blood and microdialysis sampling 
Serotonin is stored in platelet granules, and free circulating levels of serotonin are very 
low. Due to degranulation of platelets during blood sampling, large amounts of 
serotonin may leak out and cause a false, elevated serotonin concentration in plasma. 
Special techniques to prepare platelet-poor plasma (PPP) have therefore been developed 
(111, 112).
Microdialysis is based on diffusion through a semi-permeable membrane. The 
microdialysis catheter mimics a blood capillary. The tubular dialysis membrane is
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continuously perfused by a liquid that equilibrates with the surrounding interstitial fluid 
(Fig. 6). After insertion of the microdialysis catheter into the tissue, dialysate samples
can be continuously collected. The technique has been in use since the 1980s, and 
collection of serotonin from the brain is well established. It has also been used for 
determination of free serotonin in other tissues and in blood (113-117). 
Figure 6. The tip of a microdialysis catheter. The perfusion fluid is guided through the double-
lumen shaft (a). In space (b) the dialysis takes place between the inner outlet tube and the 
surrounding tubular outer dialysis membrane. The dialysate is collected (c). 
1.5 High-performance liquid chromatography (HPLC) 
Serotonin concentrations in paper II and IV were determined by HPLC. The technique 
was developed in the late 1960s and early 1970s (118). HPLC separates compounds that 
are dissolved in solution. HPLC instruments consist of a reservoir of mobile phase, a 
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pump, an injector, a separation column, and a detector. A small amount of liquid sample 
is injected into a moving stream of liquid (called the mobile phase) that passes through a 
column packed with particles of stationary phase. Separation of a mixture into its 
components depends on different degrees of retention of each component in the 
column. The extent to which a component is retained in the column is determined by its 
partitioning between the liquid mobile phase and the stationary phase.  
1.6 Echocardiography 
Cardiac ultrasonography (echocardiography) is a non-invasive tool for imaging the heart 
and surrounding structures. The evolution of ultrasonography dates back to 1880, when 
Pierre and Jacques Curie discovered piezoelectricity (119). The pioneers of 
echocardiography were Inge Edler, a cardiologist at Lund University in Sweden, and 
Hellmuth Hertz, a Swedish physicist (120). During the 1970s, Liv Hatle and Bjørn 
Angelsen in Trondheim, Norway, established the clinical use of ultrasound doppler 
(121). Diagnostic ultrasound employs pulsed, high frequency (>20 000 Hz) sound 
waves that are reflected back from body tissues and processed by the ultrasound 
machine to create characteristic images. In paper II, a GE Vingmed Ultrasound system 
Five scanner with an 8-MHz phased array probe was used to examine if leakage over 
heart valves existed. The examination was mainly performed as earlier described (122-
125).
1.7 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
In 1969, the Norwegian scientist Kjell Reppe presented a new method for “repair 
replication” at a conference in New Hampshire, which described the principles for what 
we today call PCR (126). Accordingly, Kleppe was the first to describe the theoretical 
basis of PCR, and later Kary Mullis developed it into a technique that has became one 
of the most useful techniques in molecular biology (127). Kary Mullis, but 
unfortunately not the original inventor Kjell Reppe, was awarded the Nobel Prize in 
Chemistry in 1993 for this achievement (128, 129). RT-PCR is the most sensitive 
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technique for detection of mRNA. In papers II-IV, we have used this technique to look 
at expression of serotonin receptors, the serotonin transporter and Tph in total RNA 
extracted from tissue or cell cultures. 
1.8 Cell cultures 
Primary human osteoblasts (NHOst cell system, Cambrex, Walkersville, MD, USA) and 
human mesenchymal stem cells (MSC) isolated from the iliac crest and human 
osteoclasts differentiated from human peripheral blood mononuclear cells (PBMC) were 
used in paper III. In the same paper, two immortalized cell lines, the murine MC3T3-E1 
preosteoblasts and murine RAW264.7 osteoclasts were also used. Primary cell cultures 
are initially established by dissociation of a tissue into single cells. Most cells will die as 
a result of their limited life span, which is characteristic for all somatic cells. By 
exposing normal, mortal cells to radiation, chemical carcinogens or certain oncogenic 
viruses they can be made immortalized. These cells can be dissociated by proteolytic 
treatment and subcultured (or passaged) into fresh cultures. In contrast to most primary 
cultures, immortalized cell lines are able to grow at low cell density and allow the 
cloning of single cells into homogeneous populations. However, they invariably display 
abnormal karyotypes, are in many respects already preneoplastic, and may undergo 
spontaneous transformation. Proliferation of cultured cells depends on numerous 
nutrients that are routinely supplied by a synthetic medium and on many other 
components including growth factors that are typically provided by supplementing the 
medium with serum. As serum contains large amounts of serotonin, cell culture studies 
looking at the effects of serotonin on proliferation, differentiation and release of 
mediators must be done using serotonin depleted media.  
In vitro results from cell cultures must be interpreted very carefully. In fact, cell 
lines are poor models of their in vivo counterpart. Receptors and signal transduction 
proteins are differentially expressed during embryogenesis, growth and even under 
different physiological conditions. The effects of a compound may therefore vary at 
different cell stages. Lack of circulating hormones, neurotransmitters and paracrine 
signals from neighboring cells can also make results from cell culture studies difficult to 
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interpret and firm conclusions for in vivo effects should not be drawn. Yet, to define 
mechanisms, simplified systems are necessary. The biological relevance of the findings, 
however, needs to be validated in living animals or in the human organism.  
1.9 Dual X-ray absorptiometry (DXA) 
DXA, a technique for measuring bone mineral density (BMD) and soft tissue 
composition (body fat and lean tissue mass), was used in paper IV (130). A DXA 
scanner produces two X-ray beams, each with different energy levels. One beam is high 
energy while the other is low energy. The amount of x-rays that passes through the 
tissue is measured for each beam and it will vary depending on the thickness of the 
tissue. Based on the difference between the two beams, the BMD, fat content and lean 
mass can be measured.  
1.10 Micro-computed tomography (ȝCT)
Measuring the BMD alone is not sufficient to understand how a compound or a disease 
may affect bone composition and fracture risk. In paper IV, we therefore studied the 
bone architecture by μCT (131-133). Based on the architecture, μCT can also be used to 
determine the strength and stiffness of the bone sample (134). 
1.11 Mechanical testing 
Strength and stiffness are important mechanical properties of bone. These properties can 
best be understood by examining the bone under loading. In paper IV, a three-point 
bending test was used to determine the mechanical properties of rat femurs. The test 
was performed, with a few modifiations, as earlier described (135).  
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Results and discussion 
1.1 Cells dispersed from formalin-fixed mucosa retain their 
morphological characteristics 
In paper I, the results of a new method for visualization of morphologically intact gut 
mucosal cells are shown. Due to the formalin-fixation prior to dispersion, the mucosa 
cells maintained their 3-dimensional features. The morphological description of GI 
mucosal cells has more or less been based upon histological examination of thin 
sections, resulting in 2-dimensional images (13, 136). Serial sectioning makes it 
possible to create 3-dimensional reconstructions of the histological anatomy, but the 
techniques are very time-consuming and the resulting 3-dimensional computer 
reconstructions are not telling the full truth (28).
In contrast, the current method is easy to perform and the whole procedure is done 
in a few hours. Using cell-specific antibodies, the different cell types of the cell-
suspension smears can be visualized and their morphology thus studied.  
1.2 The enterochromaffin cell has a neuron-like appearance 
EC cells have traditionally been described as bottle-shaped with apical extensions 
towards the gut lumen. A few studies have shown that they sometimes possess basal 
processes directed towards the submucosa as well (27, 28, 137). We found that 
practically all EC cells posessed projections towards the lumen and that “closed” EC 
cells, without luminal contact, are very rare. This finding underlines that EC cell 
function is to sense and respond to changes in the luminal content (14). A large 
population of EC cells, especially in the colon and in the rectum, had very long 
extensions, projecting from the base of the cells as well. These extensions were directed 
towards the base of neighboring cells and in some cases also into the lamina propria. A 
few EC cells had extensions that connected with neuron-like structures. All EC cell 
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extensions, the luminal as well as those at the base of the cells, had serotonin containing 
granules throughout their whole length. The EC cells thus have the anatomic basis to 
sense changes in the gut content and directly pass on the information to neighboring 
cells, the capillary net or to neuron endings in the lamina propria, using serotonin as the 
messenger. These findings are in accordance with the paraneuron concept which points 
out the resemblance between neuroendocrine cells and neurons (5). It has been 
suggested that EC cells are lacking in vertebrates only when there is an innervation of 
the gut mucosa by nerve fibers containing high concentrations of serotonin (138-140). 
As EC cells have serotonin-containing axon-like projections that probably make 
synaptic contact with other cells and neurons, it is tempting to suggest that EC cells are 
specialized serotonergic neurons. Differentiated EC cells with the ability to divide were 
also found, casting further doubt on a role for a local mucosal stem cell in EC cell 
renewal (141). The striking resemblance between EC cells and serotonergic neurons 
indicates that they may be neural crest derived, as stated already in the 1960s (4). It is 
therefore possible that the well accepted local stemcell theory, suggesting that all gut 
mucosal cells derive from a common local stemcell, may be wrong (7, 142). 
1.3 An animal model for the carcinoid syndrome  
By injecting rats with high doses of serotonin a carcinoid syndrome-like condition was 
created (paper II). The carcinoid syndrome is caused by high circulating levels of 
vasoactive substances secreted by carcinoid tumors arising from EC cells. The major 
pharmacologic agent causing diarrhea in the carcinoid syndrome has been proven to be 
serotonin (143). Substances like histamine, kinins and tachykinins have been reported to 
cause the periodical flushing seen in the carcinoid syndrome, but a correlation to high 
levels of serotonin and catecholamines has also been shown (39, 144-146). In the 
current study, clinical signs as loose stools and flushing were seen as a result of 
serotonin injections. The flushing appeared only a few minutes after the injections, 
indicating a direct correlation between serotonin and flushing. 
 Determination of free serotonin in plasma is hard to accomplish due to 
degranulation of the serotonin storages in platelets. Despite that protocols to avoid 
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platelet degranulation were followed, serotonin levels were extremely high in PPP 
(10 940 ± 739.2 nM) after serotonin injections. To be sure that the high PPP serotonin 
levels seen reflected the free circulating serotonin levels, microdialysis in the femoral 
muscles was performed. The basal level of serotonin in microdialysate was below the 
detection limit for the HPLC method used in paper II. The improved HPLC method 
used in paper IV, however, showed that microdialysate from the femoral muscles in a 
control rat contained 2.8 nM serotonin, which was less than one 10th of the serotonin 
level seen in PPP (51.8 nM) of control rats. Serotonin injections resulted in a peak 
concentration in microdialysate after 2 h (302 ± 11 nM), and thus a 100-fold increase 
compared to control. The serotonin concentration remained manifold increased for more 
than 6 hours. The serotonin injections induced a carcinoid-like syndrome both regarding 
clinical signs and the level of free circulating serotonin. Microdialysis seems to be the 
most accurate way to collect samples for determination of free circulating serotonin.  
1.4 Serotonin administration induces a carcinoid heart-like 
condition in rats
Echocardiographic examination of rats with hyperserotoninemia demonstrated that a 
similar heart valve leakage as seen in the carcinoid heart disease had developed (43). 
The echocardiographic results correlated with the histopathological findings of 
thickened and retracted aortic cusps with carcinoid heart-like plaque formation. Rat 
aortic cusps expressed mRNA for the 5-HT1A, 2A and 2B receptors, confirming that one or 
more of these receptors may be involved in the pathogenesis of carcinoid heart disease 
(55, 56, 60, 147). The 5-HTT was also expressed, indicating that SSRIs like fluoxetine 
have the potential to affect heart valves via a local increase in serotonin (148, 149). No 
clinical studies, however, have so far been able demonstrate any negative cardiac effects 
of these drugs (150). The fact that long-term serotonin administration induces a 
carcinoid heart-like disease in rats, suggests that serotonin is the agent causing the 
carcinoid heart disease in humans.  
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1.5 Serotonin affects bone metabolism   
It has previously been shown that functional serotonin receptors are present in 
osteoblast precursors, osteoblasts and osteocytes (97). In paper III, we demonstrated 
that the proliferative effect of serotonin on preosteoblasts was mediated, at least partly, 
through binding to 5-HT2 receptors and activation of the PKC pathway. In MSC and 
NHO cells, 5-HT2A receptor expression was found to be up-regulated by serotonin, 
indicating that this receptor is involved in the proliferation induced by serotonin in these 
cells. The effect of serotonin was biphasic, which is also known from studies on other 
cell types (151-153). Serotonin also affected osteoclast proliferation in vitro. A direct 
stimulation of osteoclast proliferation as well as differentiation and activity in a 
resorption pit assay was seen. On the other hand, serotonin increased the OPG/RANKL 
ratio in osteoblast cultures. The OPG/RANKL system is known as the most potent 
regulator of osteoclast formation and activity (76, 154), indicating that the overall effect 
of serotonin on osteoclast activity in vivo may be inhibitory. As demonstrated in paper 
IV, serotonin administration leads to higher BMD and thicker cortex in the femur 
metaphysis in growing rats. The femur perimeter, however, was not different from 
control rats and the bone marrow volume was lower, indicating that the increased 
cortical thickness could be due to an increased apposition of endosteal bone or perhaps 
also result from a reduced osteoclast activity leading to less endosteal bone resorption. 
 The changes in bone architecture also altered mechanical properties in femurs 
collected from serotonin dosed rats. As a result of a thicker cortex and less trabecular 
bone, the bones were stiffer.
 Both osteoblasts and osteoclasts expressed Tph 1, indicating that they, like 
fibroblasts and macrophages, may be able to produce serotonin (155, 156). It is thus 
possible that serotonin is a coupling factor, regulating osteoblast and osteoclast activity.
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1.6 Fluoxetine affects bone metabolism in vitro
As shown in paper III, fluoxetine induced proliferation of human MSC and osteoblasts, 
as well as murine MC3T3-E1 preosteoblasts in nM concentrations. On the contrary, ȝM
concentrations had an inhibitory effect on MSC and MC3T3-E1 cell proliferation. The 
proliferative effect seen at lower concentrations may be of less importance as the serum 
levels of fluoxetine in patients treated with this drug are 0.65–2.5 ȝM (fluoxetine + 
norfluoxetine) and the bone marrow concentration of fluoxetine may be as high as 100 
ȝM (157). Fluoxetine had a similar direct effect on osteoclast proliferation and also on 
osteoclast differentiation and activity; at nM concentrations osteoclast proliferation, 
differentiation and activity were increased, whereas concentrations > 1 ȝM were 
inhibitory. On the other hand, fluoxetine suppressed the OPG/RANKL ratio at all 
concentrations, indicating increased osteoclast formation and activation. Fluoxetine has 
been shown to affect bone mass negatively in rats, and in humans there are indications 
for an increased fracture risk and reduced growth in children using the drug (158-161).  
The overall fluoxetine effect on bone thus seems to be negative both in vitro and in vivo.
Fluoxetine did not induce serotonin elevation in the media and addition of 
serotonin to the media tended to reverse the fluoxetine effects on osteoblast 
proliferation. In addition, antagonists of the 5-HT2 receptors also reversed fluoxetine-
induced effects. It is therefore plausible that fluoxetine exerts direct effects on bone 
cells via 5-HT2 receptors and not indirectly through inhibition of serotonin reuptake by 
blocking 5-HTT. Fluoxetine has been demonstrated to have affinity for these receptors, 
which supports this theory (148, 149, 162). 
32
Conclusions
1 Dispersion of formalin-fixed gut mucosa is a new method to 
investigate single gut mucosa cell morphology. 
2 EC cells have a neuron-like appearance. 
3 Daily subcutaneous injections with serotonin results in a carcinoid 
syndrome-like condition in rats. 
4 Long-term hyperserotoninemia leads to a carcinoid heart-like 
condition in rats. 
5 Serotonin directly affects proliferation of osteoblastic cells via 
binding to 5-HT2 receptors and subsequent activation of the PKC 
pathway.
6 Serotonin increases the OPG/RANKL ratio in vitro.
7 Serotonin affects osteoclast proliferation, differentiation and 
activation in a bell-shaped manner in vitro.
8 Long-term hyperserotoninemia results in a higher total body BMD in 
rats.
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9 Long-term hyperserotoninemia leads to a thicker femoral cortex and 
a smaller bone marrow cavity in rats. 
10 Long-term hyperserotoninemia alters bone mechanical properties in 
rats.
11 Fluoxetine has a biphasic effect on osteoblast and osteoclast 
proliferation in vitro.
12 Fluoxetine reduces the OPG/RANKL ratio in vitro.
13 Fluoxetine seems to have an overall negative effect on bone 
metabolism in vitro.
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Abstract
Background: Enterochromaffin (EC) cells in the gastrointestinal tract have important 
functions as regulators of secretion, motility and sensation. The EC cell has 
traditionally been described as bottle-shaped with basally located stores of serotonin. 
Stimuli acting on the apical membrane trigger serotonin release, which in turn 
activates the sub-epithelial sensory nerve terminals. To better describe the EC cells 
appearance we developed a new method for visualization of mucosal cells.
Methods: The stomach, small intestine and large intestine were excised from Sprague 
Dawley rats and then fixed in formalin. The organs were everted and filled with 
pronase solution. Single cells and aggregates of formalin-fixed mucosal cells were 
collected by scraping the mucosa off the muscularis mucosa. EC cells were visualized 
by staining for immunoreactivity against serotonin. 
Results: EC cells with luminal extensions and very long (up to 80 ȝM) basally 
located axon-like extensions, sometimes connecting to neuron-like structures were 
found. Other EC cells had no or only short and blunt basal extensions. Dividing, 
serotonin-containing EC cells were also seen.
Conclusions: These findings may be of importance to further understand EC cell 
function in gastrointestinal physiology. The new method described can easily be 
applied to better visualize the morphology of other mucosal cells as well. 
Key words: Enterochromaffin cells, immunohistochemistry, morphology,
neuroendocrine
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Introduction 
The EC cells of the gut are characterized by their high content of serotonin (5-
hydroxytryptamine (5-HT)). They comprise the major population of gut endocrine 
cells and play a pivotal role in several aspects of gut function including secretion, 
motility and sensation [1]. EC cells are distributed all along the gastrointestinal tract, 
from the cardia to the anus [2]. Serotonin producing tumours arising from EC cells 
lead to the carcinoid syndrome [3] and hyperserotoninemia has also been shown to 
cause a carcinoid heart like disease [4]. The EC cell population seems to include 
several different sub-populations [5]. Morphological differences in shape, luminal 
endings and secretory granules suggest region-specific functions. Most EC cells are of 
the “open” type with apical cytoplasmatic extensions which project into the glandular 
lumen with short microvilli. These structures represent the anatomical basis for the 
cell response to physical or chemical variations in luminal content [6]. EC cells are 
believed to function as sensory transducers that activate mucosal processes of both 
intrinsic and extrinsic primary afferent neurons through their release of serotonin [1].
In biopsies from human duodenum, fibres showing serotonin 
immunoreactivity (IR) at the base of EC cells have been seen [7]. These fibres were 
proposed to be either infra-basal projections of the cells or branches of the enteric 
nervous system. Cytoplasmic processes sometimes projecting into adjacent glands 
have also been shown, suggesting a role for EC cells in functional synchronization 
among neighbouring glands [8,9]. Synaptic contact between EC cell extensions and 
underlying nerve fibres has not been demonstrated. 
To further investigate the appearance of EC cells we have developed a method 
for visualization of formalin-fixed, single mucosal cells and described the 
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morphology of EC cell sub-populations in different regions of the rat gastrointestinal 
tract.  
Materials and Methods
Buffers
Buffer A consisted of: NaCl 80 mM, KCl 5.0 mM, NaH2PO4 0.5 mM, 
Na2HPO4 1.0 mM, N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) 
50 mM, glucose 11 mM, NaHCO3 20 mM, ethylenediaminetetraacetic acid (EDTA) 
2.0 mM and bovine serum albumin (BSA) 10 g/L. Buffer B was analogous to buffer 
A, but contained CaCl2 1.0 mM and MgCl2 1.5 mM instead of EDTA and BSA 1.0 
g/L. Both buffers were adjusted to pH 7.4. 
Cell fixation and isolation 
The animal experiments were approved by the Animal Welfare Committee of 
the University Hospital of Trondheim, Norway. Female Sprague-Dawley rats 
(Møllegaard’s Breeding Center, Skensved, Denmark) (~200 g) were housed under 
standard conditions with free access to food and water. The rats were killed by gas 
(CO2) and the different parts of the gastrointestinal-tract (rectum, colon, ileum, 
jejunum, duodenum and antrum) were collected and washed clean of content in 0.9 % 
saline. The organs were then fixed in 4% buffered formaldehyde at room temperature. 
After fixation the sacks were carefully everted and filled with pronase solution (7.5 
mg/mL buffer A) (Merck cat no 1074330001, Darmstadt, Germany) until maximally 
extended and put in buffer A. The dispersion was performed at 37qC, one hour for the 
antrum and 30 minutes for the intestine. Cell suspensions were prepared by gently 
scraping the mucosa off the muscularis mucosa and dissolving it in buffer B.  
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Whole wall specimens from the rectum, colon, ileum, jejunum, duodenum and 
antrum were fixed by immersion in 4% buffered formalin. Following dehydration of 
the specimens and embedding in paraffin, 10 μm thick sections were cut 
perpendicularly to the mucosal surface.  
Immunohistochemistry
 Cell smears for immunohistochemistry were prepared by placing a drop of 
each cell suspension on glass slides, followed by air drying over night. The cells were 
then rehydrated and treated with 3% hydrogen peroxide for 10 min to block 
endogenous peroxidase activity. Rat monoclonal anti-serotonin (ab6336, Abcam 
Limited, Cambridgeshire, UK) was diluted (1:75) in PBS containing 0.25% Triton X-
100 (Calbiochem, San Diego, CA, USA) and 0.25% BSA (Sigma, St Louis, MO, 
USA). The cell smears were incubated with primary antiserum for 2 hours at room 
temperature. An EnVision-HRP kit (K5007, Dako, Glostrup, Denmark) and an AEC 
peroxidase kit (SK4200; Vector, Burlingame, CA, USA) were used to visualize the 
immunoreaction. We also performed immunohistochemistry on 10 ȝM sections from 
paraffin embedded tissue. Except for deparaffinization the procedure described above 
was used for serotonin immunostaining of the sections as well. Most preparations 
were lightly counterstained with hematoxylin.
Results
In the rectum, the vast majority of EC cells was of the “open” type with 
luminal extensions. In some cases the dispersed EC cells were still attached to one or 
more mucosal cells. Two morphologically distinct subpopulations of EC cells were 
found. One of the subpopulations had a luminal extension and two or more relatively 
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short (10-15 ȝm) and blunt basal extensions containing serotonin granules (Fig. 1A).
The body and nucleus of these cells appeared to lie in the glands. The other 
subpopulation had very long (50-80 ȝm) and thin basal extensions (Fig. 1B). The 
basal extensions had serotonin containing granules and often demonstrated a terminal 
button with accumulation of serotonin. The cell bodies were in some cases located 
outside the glands but the cells were still in contact with the lumen via slender luminal 
projections. The EC cells in the colon also comprised two distinct sub-populations 
similar to those seen in the rectum (Fig. 2). In a few cases we found EC cells with 
long basal extensions and terminal buttons connecting to neuron-like (dendrites?) 
structures without serotonin IR. In traditional histological sections from the colon, 
basal extensions seemed to surround the glands. Serotonin positive fibres were also 
seen in the lamina propria (Fig. 3). 
In the ileum, jejunum and in the duodenum (Fig. 4A), most cells had an apical 
projection but no basal extensions. When present (~ 10 %), the basal extensions were 
shorter than in the large intestine but they had a similar appearance, with serotonin 
containing granules and sometimes terminal buttons. 
The antral EC cells constituted a less homogeneous population (Fig. 4B). 
Some cells had luminal projections and short basal extensions. Others had a spider-
like appearance with multiple extensions. As these cells rarely were attached to 
neighbour cells, the direction of the extensions could not be determined. When whole 
antral glands were preserved, EC cells in contact with other EC cells were 
demonstrated. EC cells without distinct projections were seen in less then five percent 
of all examined parts of the gastrointestinal tract. These could represent a mature 
“closed” type of EC cells or perhaps non-mature EC cells. A few serotonin IR cells 
undergoing mitosis were also demonstrated (Fig. 5). 
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Discussion
This study demonstrates a new technique for visualization of formalin-fixed 
gut mucosa cells. Despite its simplicity, it elicits new insights concerning three-
dimensional features at the single mucosa-cell level. We have applied the method to 
describe the appearance of EC cells in different parts of the rat gastrointestinal tract, 
but it can easily be applied on other mucosal cells as well.
The dispersed formalin-fixed EC cells possessed very long and extremely thin 
extensions, indicating that the dispersion technique had been gentle. Serotonin 
negative mucosal cells did not show basally located elongations. It is not likely that 
this difference between serotonin positive cells and other mucosal cells was due to 
artefacts. The protease digestion and mechanical dispersion may affect the cell 
anatomy to some extent, major morphological features, however, seem to be 
preserved.
Prior studies using thymidine labelling have suggested that EC cells are 
renewed by self-proliferation [10-12]. These results were confirmed in our study by 
the finding of dividing EC cells. Previous descriptions of EC cells have been based on 
standard specimen preparation, sectioning and histological examination, which results 
in a 2-dimensional picture. We found EC cells with basal projections as long as 80 
ȝM and only 0.1 ȝM thick. As these projections seemed to be headed in different 
directions, traditional techniques, including serial sectioning, may have failed to fully 
visualize them [2,5,9]. While EC cells have been described as open or closed 
regarding their contact with the gut lumen [5], the present study illustrates that most 
EC cells seem to have luminal contact, even when the body of the cell lies outside the 
gland. This is not surprising as EC cells are believed to sense and respond to 
variations in luminal content. In some cases however, especially in antrum, the EC 
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cells were not attached to neighbour cells after dispergation, making it difficult to 
determine whether they were of the closed or open type. 
The resemblance between gut endocrine cells and nerve cells gave birth to the 
“paraneuron” concept [13]. The microvilli were regarded as the sensory part of the 
nerve cell, the cell body as the signal transport portion and the exocytosed secretory 
granules as the message. In recent studies, serotonergic neurons in the medulla and in 
the midbrain have been found to act as chemoreceptors [14] and others have shown 
that mouse taste buds use serotonin as a neurotransmitter [15]. From an evolutionary 
perspective, it has been suggested that EC cells in vertebrates are lacking only where 
there is an innervation of the gut mucosa by nerve fibres containing high 
concentrations of serotonin [16-18]. We found that EC cells have serotonin-
containing axon-like projections, sometimes connecting with neuron-like structures. 
The idea that EC cells are of neural crest origin was first put forward by Pearse et.al.
[19] and has later been supported by others [20]. This theory, however, has later been 
opposed and most researchers in the field now believe that gut neuroendocrine cells 
are derived from a local endodermal stem cell [21,22]. If the endodermal stem cell 
theory is correct, sensory serotonergic neurons in the gut mucosa have been replaced 
during evolution by EC cells, which have striking morphological similarities with 
neurons, but different embryological origin. As shown in this study, serotonin-
producing EC cells like adult endocrine cells in the pancreas [23] and 
enterochromaffin-like cells in the stomach [24], are able to divide. The fact that 
differentiated EC cells can replicate cast further doubt on the idea that mucosal stem 
cells have a role in EC cell renewal.
As dispersed mucosal cells have lost contact with underlying structures, the 
targets for the basal EC cell extensions were not possible to demonstrate. In 
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traditional histological sections, however, serotonin IR fibres were seen in the lamina
propria and similar fibres seemed to surround glands. It is likely that these fibres 
represent the projections that we found at the base of dispersed formalin-fixed cells. 
The EC cell may thus function as a primary neuron, sending its message to neurons in 
lamina propria [25,26]. Others have proposed that EC cells send instant paracrine 
messages to neighbouring cells through long cytoplasmatic extensions and thus 
initiate a functional synchronization among neighbouring gland cells [8,9]. A similar 
function has also been proposed for somatostatin producing cells in the stomach [27]. 
The third and fourth type of EC cells that we found had only short and thick basal 
extensions or no basal extensions at all. These cells had large amounts of serotonin 
stored in basally located granules. A possible function for these cells could be to 
release their hormonally active content to fenestrated capillaries or perhaps also work 
paracrine on cells in the lamina propria.
The current work gives new important insights in EC cell morphology. These 
findings might be helpful in order to further understand the EC cells role as a 
regulator of gastrointestinal physiology. The method described can also be used to 
isolate and visualize other morphologically intact GI mucosal cell types. 
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Figure 1.  Photomicrographs showing serotonin immunolabelled, formalin-fixed EC 
cells (red) dispersed from the rectal mucosa. (A) Cells with luminal projections and 
thick basal projections with accumulation of serotonin containing granules. (B) Cells 
with long and slender, axon-like, basally located extensions with serotonin containing 
granules. The EC cells are in some cases attached to neighbour mucosa cells. 
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Figure 2.   Photomicrographs showing serotonin immunolabelled, formalin-fixed EC 
cells (red) dispersed from the colonic mucosa. All cells have luminal projections. 
Left, four cells with one or two basally located, axon-like projections are seen. The 
fourth cell from the left connects with a neuron-like structure. Right, a cell with short 
and blunt basal projections. The EC cells are in some cases attached to neighbour 
mucosa cells.
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Figure 3.   Photomicrographs of 10 μm thick serotonin immunolabelled colon 
sections. Left, a serotonin containing fibre in the lamina propria. Right, EC cells with 
extensions surrounding the gland. Counterstained with haematoxylin. 
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Figure 4.   (A) Photomicrographs showing serotonin immunolabelled, formalin-fixed 
EC cells (red) dispersed from the small intestine. Left, EC cells with luminal 
projections, but no basal extensions. These cells have an accumulation of infra-
nuclear serotonin containing granules. Right, three EC cells with both apical and basal 
extensions. (B) EC cells dispersed from the antral mucosa. Left, two cells with 
luminal extensions and short serotonin containing basal extensions. In the middle, a 
more spider-like cell with multiple thin extensions. Right, two EC cells located in a 
gastric gland. The EC cells are in some cases attached to neighbour mucosa cells. 
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Figure 5.   Photomicrographs showing serotonin immunolabelled, formalin-fixed EC 
cells dispersed from the jejunal mucosa. Left, a dividing cell with a non-granulated 
serotonin positive cytoplasm. Right, three EC cells with an immature appearance.  
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Abstract
      Recent studies have proposed a role for serotonin and its transporter in regulation of bone 
cell function. In the present study we examined the in vitro effects of serotonin and the 
serotonin transporter inhibitor fluoxetine “Prozac” on osteoblasts and osteoclasts. Human 
mononuclear cells were differentiated into osteoclasts in the presence of serotonin or 
fluoxetine. Both compounds affected the total number of differentiated osteoclasts as well as 
bone resorption in a bell-shaped manner. RT-PCR on the human osteoclasts demonstrated 
several serotonin receptors, the serotonin transporter and the rate limiting enzyme in serotonin 
synthesis, tryptophan hydroxylase 1 (Tph1). Tph1 expression was also found in murine 
osteoblasts and osteoclasts, indicating an ability to produce serotonin. In murine 
preosteoclasts (RAW264.7) serotonin as well as fluoxetine affected proliferation and NFțB
activity in a biphasic manner. Proliferation of human mesenchymal stem cells (MSC) and 
primary osteoblasts (NHO), and 5-HT2A receptor expression were enhanced by serotonin. 
Fluoxetine stimulated proliferation of MSC and murine preosteoblasts (MC3T3-E1) in nM 
concentrations, μM concentrations were inhibitory. The effect of fluoxetine seemed direct, 
probably through 5-HT2 receptors. Serotonin-induced proliferation of MC3T3-E1 cells was 
inhibited by the PKC inhibitor (GF109203) and was also markedly reduced when antagonists 
of the serotonin receptors 5-HT2B/C or 5-HT2A/C were added. Serotonin increased OPG and 
decreased RANKL secretion from osteoblasts, suggesting a role in osteoblast-induced 
inhibition of osteoclast differentiation, whereas fluoxetine had the opposite effect. This study 
further describes possible mechanisms by which serotonin and the serotonin transporter can 
affect bone cell function.
2
Introduction
Serotonin (5-hydroxytryptamine or 5-HT) is a well-known amine neurotransmitter. Outside 
the central nervous system serotonin is mainly produced by the enterochromaffin cells of the 
gut and participates in the regulation of intestinal motility, fluid secretion and regional blood 
flow (1). After release, serotonin is rapidly taken up by an active transport mechanism into a 
number of cell types, with platelets serving as the major reservoir. Serotonin is a vasoactive 
substance with an important role in systemic blood pressure regulation (2) and mediates its 
actions by interacting with multiple serotonin receptor subtypes (3). Studies on cell cultures 
have shown that serotonin has mitogenic effects on fibroblasts (4), smooth muscle cells (5) 
and vascular endothelial cells (6) mediated through 5-HT2 receptors. We recently 
demonstrated that long-term administration of toxic doses of serotonin leads to a carcinoid 
heart like condition with myofibroblast proliferation and plaque formation on heart valves in 
rats (7). Serotonin administration also induced a significant increase in bone mineral density 
compared to control rats, indicating that serotonin has a positive effect on bone formation (8). 
   The 5-HT1A and 5-HT2 receptors have been demonstrated in both monocytes and 
macrophages, and serotonin is known to exert direct effects on the immune system (9). It has 
also been suggested that platelets and macrophages are able to produce serotonin (10, 11). 
Our group and others have previously demonstrated functional serotonin receptors and 
serotonergic pathways in bone cells (12-14). An increased expression of 5-HTT in 
RAW264.7 cells stimulated with RANKL has been described and fluoxetine seemed to inhibit 
differentiation in these cells, suggesting reduced bone resorption (14). In a recent study 
however, long-term treatment with the 5-HTT inhibitor (selective serotonin reuptake 
inhibitor, SSRI) fluoxetine led to reduced bone accrual in growing mice (15).  
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   Receptor activator of NFțB Ligand (RANKL) and its inhibiting decoy receptor 
osteoprotegerin (OPG) are central in osteoclast regulation (16, 17). RANKL, secreted mainly 
by osteoblastic stromal cells, is necessary for osteoclast formation from its committed 
precursors, which bear its receptor RANK. The cytokine IL-6 also has osteoclastic actions, 
acting via RANKL/OPG alterations (18). Activation of RANK leads to activation of 
downstream signaling pathways including NFțB, p38 kinase, and c-Jun N-terminal kinase 
(JNK) (19). Stimulation of JNK subsequently elicits the activation of the transcription factor 
c-Jun (20). c–Jun forms activator protein-1 (AP-1) complexes with cFos, an essential 
transcription factor for osteoclast formation (21). The AP-1 complex is also known to be 
involved in regulation of osteoblast proliferation and differentiation (22).
   The aim of the present study was to investigate the effects of serotonin and fluoxetine on 
human and murine osteoblast as well as osteoclast proliferation and differentiation. We also 
wanted to examine which intra-cellular pathways might be involved. In addition, we have 
studied OPG, RANKL release from serotonin and fluoxetine-treated murine preosteoblasts.
Materials and methods
Cells
     MC3T3-E1 (murine preosteoblasts, ATCC) cells were maintained in D-MEM (Invitrogen) 
supplemented with 10 % fetal calf serum (FCS) (Biological Industries), 1 mM Na- pyruvate 
(Gibco), 0.1 mg/ml L-glutamine (Gibco) and 10 U/ml penicillin/streptomycin (Gibco). 
RAW264.7 (murine preosteoclast, ATCC) cells were maintained in DMEM with 4.5 g/l 
glucose (Gibco), supplemented with 1 mM Na- pyruvate, 0.1 mg/ml L-glutamine, 10 U/ml 
penicillin/streptomycin and 10 % FCS. The IL-6 dependent mouse hybridoma cell line B9 
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was cultured in RPMI 1640 (Gibco) medium containing 10 % FCS, 2-mercaptoethanol (50 
PM) and IL-6 (1 ng/ml)(Biosource). All cell studies were performed with a cell passage less 
then 25. 
   MC3T3-E1 cells were differentiated by addition of ascorbic acid (25 μg/ml) (Sigma) and E-
glycerophosphate (3 mM) (Sigma) to the growth medium (23-25). RAW264.7 cells were 
differentiated by addition of sRANKL (50 ng/ml) (Research Diagnostics, INC) and M-CSF 
(50 ng/ml) (Research Diagnostics, INC).  
   Human mesenchymal stem cells (MSC) were isolated from the iliac crest (MSC). 
Lymphoprep (AXIS-SHIELDPoC A/ S, Oslo, Norway) was used to isolate the mononuclear 
cells from the bone marrow. The mononuclear cells were pelleted and cultured in MEM 
Alpha medium (Invitrogen life technologies, Grand Island, USA) with 20 % FCS, 100 U/ ml 
penicillin, and 0.1 mg/ ml streptomycin. The cells were maintained in humidified 95% air 5% 
CO2 atmosphere at 37oC. Half of the medium was changed twice weekly and the cells were 
subcultured using 0.05% trypsin with 0.01% EDTA prior to experiments. Donor recruitment 
and acquisition of human bone marrow were performed in accordance with a protocol 
approved by the local ethical committee.  
   Commercially available primary human osteoblasts from both femur and tibia of different 
donors (NHOst cell system, Cambrex, Walkersville, MD, USA) were grown in Osteoblast 
Growth Media (OGM, Cambrex). Osteoblasts cultured to facilitate mineralization were 
exposed to hydrocortisone hemisuccinate (200 nM) and E-glycerophosphate (10 mM) 
(Cambrex) in the ambient medium. The phenotype of the cells was characterized based on the 
expression levels of alkaline phosphatase (ALP), collagen type 1, osteocalcin and CD44, and 
formation of mineralization nodules. 
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RT-PCR
   Total RNA was isolated from human osteoclasts differentiated from human peripheral blood 
mononuclear cells (PBMC) using RNeasy Midi Kits (Qiagen). RT-PCR was performed on 
total RNA from human osteoclasts according to standard procedures using the One-step RT-
PCR Kit (Qiagen), and 40 cycles of amplification. For analysis of Tph1 mRNA from MC3T3-
E1 and RAW264.7, 1 μg of total RNA was subjected to cDNA synthesis using M-MuLV 
Reverse Transcriptase (Applied Biosystems) and oligo-dT primer, according to the 
manufactures protocol. The cDNA was amplified using the HotMaster Taq DNA Polymerase 
Kit (Eppendorf).
   PCR-products were cloned into the pCRII-TOPO vector using the TOPO TA Cloning Kit 
(Invitrogen) for sequencing, according to the standard protocol. Vectors containing PCR 
products were transformed by heat shock into One Shot DH5D -T1 cells (Invitrogen), and 
isolated by the SpinClean Plasmid Miniprep Kit (Mbiotech). Products were sequenced using 
the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the 
manufactures protocol. Primers are listed in Table 1. 
   MSC and NHO Cells were lysed in lysis/binding buffer (100 mM Tris-HCl, pH 8.0, 500
mM LiCl, 10 mM EDTA, pH 8.0, 0.5 mM dithiothreitol [DTT], and 1% sodium dodecyl 
sulfate [SDS]). mRNA was isolated using magnetic beads [oligo (dT)25] as described by the 
manufacturer (Dynal AS, Oslo, Norway). Beads containing mRNA were re-suspended in 10
mM Tris-HCl, pH 8.0, and stored at -70°C until use. One μl of the mRNA-containing solution 
was applied directly to obtain a first-strand complementary DNA (cDNA) using the iScript 
cDNA Synthesis Kit which contains both oligo(dT) and random hexamer primers (Bio-Rad, 
Hercules, CA, USA). RT-PCR reactions were performed and monitored using iCycler iQ 
(Bio-Rad, Hercules, CA, USA). The 2X iQ SYBR Green Supermix was based on iTaq DNA 
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polymerase (Bio-Rad, Hercules, CA, USA). cDNA samples were analyzed for the genes of 
interest and the reference genes GAPDH. The amplification program consisted of a pre-
incubation step for denaturation of the template cDNA (3 min 95 qC), followed by 50 cycles 
consisting of a denaturation step (15 s 95qC), an annealing step (30 s 60qC) and an extension 
step (30 s 72qC). After each cycle, fluorescence was measured at 72qC. A negative control 
without cDNA template was run in each assay. Samples were run in duplicate. To allow 
relative quantification after PCR, standard curves were constructed from the standard 
reactions for each target and housekeeping genes by plotting Ct values, i.e. the cycle number 
at which the fluorescence signal exceeds background, versus log cDNA dilution. The Ct 
readings for each of the unknown samples were then used to calculate the amount of either the 
target or housekeeping relative to the standard. mRNA levels were calculated as the ratio of 
relative concentration for the target genes relative to that for the mean between housekeeping 
genes. Oligonucleotide primer sequences used for the real-time RT-PCR and the specific 
parameters are shown in Table 1. Real-time efficiencies were calculated from the given slopes 
in the iCycler software using serial dilutions, showing all the investigated transcripts high 
real-time PCR efficiency rates, and high linearity (r > 0.99) when different concentrations 
were used. PCR products were subjected to a melting curve analysis on the iCycler and 
subsequently 2 % agarose/TAE gel electrophoresis to confirm amplification specificity, Tm
and amplicon size, respectively (see Table 1).  
Human osteoclast differentiation
   Osteoclasts were differentiated from PBMC (26), isolated from buffycoat. Separation of 
PBMC was performed essentially as described by Bøyum (27). Cells were seeded into 24-
well dishes, 500 000 cells/well in D-MEM including M-CSF and RANKL (50 ng/ml), and 
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dexamethasone (0.01 PM) (Sigma). Assays were performed in triplicate. The medium was 
replaced at day six and nine. After 12 days the cells were stained for tartrate resistant acid 
phosphatase (TRAP) using the Sigma diagnostics acid phosphatase kit (Sigma), as described 
by the manufacturer. TRAP positive, multinuclear (three or more nuclei) cells were regarded 
as genuine osteoclasts. The 5-HT2A/C receptor antagonist ketanserin and fluoxetine were 
purchased from Sigma. To develop into osteoclasts, PBMC cells need serum in addition to 
differentiation factors in the medium. Since FCS is known to contain rather high levels of 
serotonin (14), we determined the amount of serotonin contamination in the media using a 
serotonin RIA kit (Dianova AS, Nesbru Norge). The sensitivity for the kit was 4 ng/ml. 
   In order to investigate direct osteoclast activity a pit resorption assay was performed. The 
PBMC cells were seeded on BioCoat Osteologic Discs (BD Biosciences) and cultured as 
described above. Bone resorption was determined with the BD Biocoat Osteologic Bone Cell 
Culture System (BD Biosciences) according to the manufacturer.  
Proliferation assays 
   Cell proliferation ELISA, BrdU (chemiluminiscence) kit (Roche Molecular Biochemical’s) 
was used for the proliferation assays on murine bone cells. Two thousand cells/well were 
seeded in 96-well plates, and cultured for 24 h. Then the cells were washed once with 180 Pl
serum-free medium, before addition of new serum-free medium containing test substances. 
After five h, BrdU was added, and the cells were cultured for additional 18 h before 
incorporation of BrdU was measured as described by the manufacturer. Light emission of the 
samples, expressed as relative luminescence units (RLU), was measured in a micro-plate 
luminometer (Fluoroskan Ascent FL, Labsystems). The PKC inhibitor GF 109203x, the PKA 
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inhibitor H89 and the CAMK inhibitor W7 were obtained from Calbiochem, whereas the 5-
HT2B/C receptor antagonist SB206553B was obtained from Sigma. 
Human bone marrow cells and primary osteoblasts were seeded in 48 wells plates and 
cultured to 50 % confluency. The cells were incubated for 12 and 48 h with serum-free 
medium containing serotonin and fluoxetine and pulsed with 1 mCi 3H-thymidine per well 12 
h prior to harvest. The medium was removed and the cells washed twice with ice-cold 1 x 
PBS and twice with ice-cold 5 % TCA to remove unincorporated 3H-thymidine. The cells 
were solubilized in 500 ml NaOH (1M), and 400 ml of the solubilized cell solution was 
transferred to 8 ml of Insta-gel II Plus liquid scintillation fluid (Perkin Elmer, Applied 
Biosystems, Foster City, CA) and measured for 3 min in a liquid scintillation counter 
(Packard 1900 TR). 
Plasmids and luciferase assays 
   pFOSLuc transfection and luciferase assay in MC3T3-E1 cells: Fifteen thousand cells/well 
were seeded in 96-well plates and transfected with 0.12 Pg luciferase reporter plasmid per 
well (pcFos reporter-plasmid (nucleotides –327 to –288 of the human cFos promoter) (28), a 
generous gift from Dr. Ugo Moens (University of Tromsø, Norway)), using 0.35 Pl Fugene 
transfection reagent (Roche Molecular Biochemical’s, Germany). After cultivation for 24 h, 
cells were treated with agonist for six h. Then the cells were washed twice in PBS before 
addition of 20 Pl lysis buffer. Luciferase activity was measured by the Turner Luminometer, 
model TD-20/20 (Turner Designs) using the Luciferase reporter Assay System (Promega Inc., 
USA).
   pBIIXLuc and pFOSLuc transfection in RAW264.7 cells: The NFNB-driven plasmid 
pBIIXLuc contains two copies of a HIV-NFțB sequence cloned upstream of the mouse fos
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promoter and Photinus pyralis luciferase coding sequence, and was kindly provided by Dr. 
M. Jättelä (Danish Cancer Society, Copenhagen, Denmark). One day before the transfection, 
RAW264.7 cells were seeded in 96-well plates (50 000 cells per well). Cells were transfected 
using 0.1 μg luciferase reporter plasmid and 0.3 μl Fugene Transfection Reagent per well. 
After cultivation for 24 h, cells were treated with agonist for 6 h in serum-free medium. The 
cells were then washed with PBS followed by lysis in 15 Pl lysis buffer. Luciferase activity 
was measured.  
OPG, RANKL and IL-6 release assays 
Release of OPG, IL-6, RANKL and amount of total protein were studied in medium 
samples collected from MC3T3-E1 cells. Thirty thousand cells in 0.5 ml MEM-D supplied 
with 10 % FCS/well were seeded in 24-well plates. After 24 h, cells were washed and 
cultured in 0.5 ml serum-free medium for an additional 24 h. Then fresh serum-free medium 
containing test substances was added. Cells were cultured up to 72 h, medium samples were 
harvested and frozen (-20°C) until release assays were performed. 
   The concentration of OPG in culture media was determined by ELISA. Briefly, 96-well 
plates were coated with 2 μg/ml anti-mouse-OPG-antibody (R&D Systems). The OPG 
standard curve was generated using recombinant mouse OPG (R&D Systems) in two-fold 
dilutions from 2000 to 31.25 pg/ml. The secondary antibody was biotinylated anti-mouse 
OPG (200 ng/ml) (R&D Systems), and detection was carried out using streptavidin-
horseradish peroxidase (R&D Systems) in combination with OPD-substrate tablets (Dako). 
Samples were then incubated for 20 minutes in the dark after which the reaction was stopped 
by addition of 1 M H2SO4, and absorbance was measured at 490 nm. Minimum detectable 
concentration of mouse OPG was 10 pg/ml. According to the manufacturer no significant 
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cross-reactivity or interference has been observed. Intra-assay and inter-assay variability were 
less than 15 % and 9 %, respectively. 
   RANKL concentrations in culture media were determined by an immunoassay kit for 
quantitative determination of free sRANKL (mouse and rat; Biomedica), according to the 
manufacture’s protocol.  
   Concentrations of IL-6 in the culture medium were determined by a bioassay utilizing the 
IL-6 dependent mouse hybridoma cell-line B9. Recombinant human IL-6 (Biosource) was 
used as a standard. Fifty Pl of standard or sample were added as triplicate to a 96-well plate. 
After that mouse hybridoma B9 cells were seeded (5000 cells/well) and incubated for 3 days. 
The growth of cells was assessed by a (3-(4.5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) / phenazine methosulfate 
(PMS) reduction assay essentially as described by Buttke (29). Briefly, medium was removed, 
cells were washed with PBS and 20 Pl/well of MTS/PMS solution, (2 ml MTS (2 mg/ml in 
PBS) (Promega) and 100 Pl PMS (0.92 mg/ml in PBS) (Acros Organics)), were added, and 
plates were incubated for 4 h. The optical density of each well was measured at 490 nm. 
Minimum detectable concentration of IL-6 was typically 5 pg/ml, and intra-assay and inter-
assay variability were both less than 15 % for all measured samples.  
   Total protein in medium was determined using Sigma Microprotein PR assay kit with a 
Protein Standard Solution Calibrator (Sigma Diagnostics, Dorset, UK). Analyses were 
performed using Cobas Mira chemistry analyzer. Thirty μl of medium were mixed with 200 
μl substrate. Intra-assay and inter-assay variability were less than 2.4 % and 3.2 % 
respectively. The assay detection range was 10-2000 mg/l. 
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Lactate dehydrogenase (LDH) activity 
   LDH activity in the culture media after incubation was used as an index of cytotoxicity. 
After incubation with serotonin or fluoxetine, the culture media were collected, centrifuged at 
500 x g for 5 min at 4ºC, and the supernatant was stored at 4qC. LDH activity was determined 
spectrophotometrically according to the manufacturer's kit instructions (Cytotoxicity 
Detection kit, Roche Diagnostics, Manheim, Germany), and presented relative to the activity 
in the medium of untreated cells. 
Statistics 
   All experiments were repeated three times and the data are presented as means ± SEM. All 
data were tested for normality with Shapiro-Wilk. Normally distributed parameters were 
tested by means of Student’s T test, while parameters that were not normally distributed were 
tested with Mann-Whitney U test. Significance was assumed at p values lower than 0.05.
Results
Serotonin receptors are expressed in human osteoclasts and tryptophan hydroxylase is 
expressed in both osteoclasts and osteoblasts 
   In human PBMC differentiated into osteoclasts, the expression of 5-HT2A, B and C -receptors,
5-HTT and Tph1 was shown; the 5-HT1A receptor however was not expressed. The calcitonin 
receptor was expressed, confirming that osteoclasts had developed (Fig. 1A). Undifferentiated 
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as well as differentiated (1, 2, 3 and 4 weeks) murine preosteoclasts and preosteoblasts also 
expressed Tph1, indicating that they may be able to produce serotonin (Fig. 1B). Human MSC 
expressed 5-TH1A and 5-TH2A and NHO cells the 5-HT2A receptor. The 5-HT2B and C-
receptors, however, were not found to be expressed in these cells (data not shown). 
Serotonin stimulates osteoclast differentiation and proliferation 
Previous studies have demonstrated that monocytes express serotonin receptors (30, 31). 
We therefore examined if serotonin and its transporter could influence differentiation of 
osteoclast precursors into osteoclasts. PBMC cells were incubated with serotonin (0.01-50 
PM) or fluoxetine (0.001-10 PM) (Sigma) in addition to osteoclast differentiation factors. 
Furthermore, the effect of ketanserin (0.1-1 PM) (Sigma) on serotonin (10 PM)-induced
osteoclast differentiation was examined. We found that serotonin as well as fluoxetine 
increased the total number of differentiated human osteoclasts as well as osteoclast activity 
(Fig. 2). At higher concentrations however, the effect of fluoxetine was inhibitory. Ketanserin 
inhibited the serotonin-induced osteoclast differentiation, demonstrating involvement of 
receptors 5-HT2A and/or 5-HT2C. The control media contained serotonin (0.08 PM), due to 
contamination from FCS.  
   To confirm the data on human osteoclasts we performed a proliferation assay on RAW264.7 
cells. When serotonin (0.01-50 PM) or fluoxetine (0.001-10 PM) was added to the RAW264.7 
medium, the number of preosteoclasts also increased or decreased in a bell-shaped manner 
(Fig. 3).  Serotonin was not detectable in media from untreated RAW264.7 cells or in media 
from cells treated with fluoxetine. 
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Serotonin and fluoxetine activate cFOS and NFțB in murine preosteoclasts 
   To investigate which intracellular pathways are activated by serotonin and fluoxetine in 
osteoclasts, RAW264.7 cells were transfected with pBIIXLuc and pFos. RANKL was used as 
positive control for NFțB activation. Both cFos and NFțB were activated by serotonin and 
fluoxetine in RAW264.7 cells indicating a role in osteoclast formation for these transcription 
factors (Fig. 4). The NFțB activation was most pronounced at 0.01 ȝM for both substances 
(251 % for fluoxetine and 212 % for serotonin compared to control). At higher serotonin and 
fluoxetine concentrations NFțB activation was absent, but cFos remained activated. 
Serotonin and fluoxetine have a dose-dependent effect on osteoblast and bone marrow stem 
cell (MSC) proliferation 
   Serotonin enhances the proliferation of both NHO and MC3T3-E1 cells in a bell-shaped 
dose-dependent manner (Fig. 5A and C). Serotonin also induced a similar dose-dependent 
activation of pFosLuc in MC3T3-E1 cells (Fig. 5B), and to a lesser degree serotonin induced 
proliferation of MSC cells (Fig. 5D). 
   The PKC inhibitor GF 109203x (3.5 PM) reduced serotonin-induced proliferation, 
indicating involvement of this signaling pathway, the PKA inhibitor H89 (10 PM) and the 
CAMK inhibitor W7 (10 PM), however, had only marginal effects (Fig. 6A). The 5-HT2A/C 
receptor antagonist ketanserin and the 5-HT2B/C receptor antagonist SB206553B inhibited 
serotonin-induced osteoblast proliferation in a concentration dependent manner (Fig. 6B). The 
different inhibitors and antagonists used had no influence on proliferation of MC3T3-E1 cells 
in the absence of serotonin.
    As 5-HTT expression is found in osteoblasts we examined the effects of fluoxetine on MSC 
and osteoblast proliferation. Fluoxetine seemed to stimulate proliferation of MSC and 
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MC3T3-E1 cells at low concentrations, at higher concentrations, however, the effect was 
inhibitory (Fig. 7). This inhibitory effect could partly be reversed by ketanserin and 
SB206553B. In NHO cells fluoxetine (0.01 PM) stimulated proliferation, higher 
concentrations, however, did not affect the proliferation rate. Addition of serotonin to the 
media reversed fluoxetine-induced inhibition of proliferation of MC3T3-E1 cells and the 
enhanced proliferation by fluoxetine of NHO was also reversed by serotonin. Serotonin was 
not detectable in cells cultured with fluoxetine or in control media. Measurements of LDH in 
the media confirmed that the effect of high-dose fluoxetine was inhibitory and not cytotoxic 
(data not shown). Both serotonin and fluoxetine induced an acute (24h) decrease (to 58-85 % 
of control) in the expression of 5-TH2A receptor mRNA followed by an enhanced expression 
(to 130-186 % of control) after 48 h in  MSC, however, due to few donors and large variation 
in response between donors the effects failed to be significant.  In NHO cells, 5-TH2A receptor 
mRNA expression was enhanced significantly by serotonin. The maximum effect was seen 
with serotonin 1 PM, (264 % of control) after 24 h and (429 % of control) after 7 days (results 
not shown). 
Opposite effects of serotonin and fluoxetine on OPG and RANKL release from osteoblasts 
   Serotonin reduced the RANKL release from MC3T3-E1 (Fig. 8A). The most pronounced 
effect (to 38 % of control), was detected after 72 h incubation. Serotonin (1 PM) increased the 
OPG release (to 180 % of control) after 72 h (Fig. 8B). Fluoxetine had a divergent effect with 
a more than three fold- increase in RANKL release at the most and decrease to 43 % of 
control in OPG release (Fig. 8-D).  
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Discussion
   In this study we demonstrate that serotonin induced proliferation of human primary 
osteoblasts (NHO) and to a lesser extent also of human MSC cells. We also find that serotonin 
induced proliferation and differentiation of MC3T3 E1 preosteoblasts. Previously we have 
shown that functional serotonin receptors are present in osteoblast precursors, osteoblasts and 
osteocytes (12). Serotonin induces proliferation in cells originating from mesenchymal stem 
cells (smooth muscle cells, fibroblasts etc) via the 5-HT2 receptors (32, 33), with subsequent 
activation of different signaling pathways in a cell specific manner (34). The proliferative 
effect of serotonin on preosteoblasts seemed to be mediated, at least partly through binding to 
5-HT2 receptors and via activation of the PKC pathway. In MSC and NHO cells, 5-HT2A
receptor mRNA expression was found to be up-regulated by serotonin, indicating that this 
receptor is involved in the proliferation induced by serotonin in these cells. In all experiments 
we found a biphasic increase in proliferation, with a maximum at about 1 ȝM, while higher 
concentrations led to inhibition. This tendency is known from studies on other cell types (35-
37). Serotonin activated the cFos promotor in the MC3T3 E1 cells indicating that this 
transcription factor is involved in serotonin induced proliferation of osteoblasts. 
   Serotonin might exert its effects on bone via the blood circulation, as platelets are the main 
site of storage. However a direct effect via serotonergic neurons, innervating bone tissue is 
also possible. We showed that osteoblasts and osteoclasts expressed mRNA for Tph1, the 
rate-limiting enzyme in serotonin synthesis. We therefore propose that osteoblasts and 
osteoclasts are capable to produce serotonin, and that serotonin may act via autocrine and 
paracrine mechanisms. We could not find detectable levels of serotonin in serum-free 
osteoblast and osteoclast cell cultures, and also not after addition of fluoxetine. In vivo, bone 
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cell serotonin production may be regulated by hormonally active substances, not present in
vitro, or may be under neuronal control.  
   The therapeutic range for fluoxetine in serum is 0.65–2.5 ȝM (fluoxetine + norfluoxetine). 
A recent study indicated that the bone marrow concentration of fluoxetine can be as high as 
100 ȝM in patients taking the drug (38). The same study also showed that traces of fluoxetine 
could be detected in bone marrow three months after termination of medication. We found 
that fluoxetine induced proliferation of human MSC, osteoblasts and murine MC3T3-E1 
preosteoblasts in nM concentrations. Except for in human osteoblasts, however, ȝM
concentrations had an inhibitory effect. If the fluoxetine concentration in bone marrow is as 
high as 100 μM, our findings indicate that MSC cells and preosteoblast proliferation will be 
reduced in patients taking the drug. From earlier studies it is known that fluoxetine in addition 
to be a serotonin reuptake inhibitor also has affinity to 5-HT2A and C receptors (39-41). The 
fact that addition of serotonin together with fluoxetine did not enhance the effect, but slightly 
inhibited fluoxetine effects, suggests that the fluoxetine effect is direct and not indirect 
through inhibition of serotonin reuptake. As the fluoxetine effects could be, at least partly, 
blocked by the 5-HT2B/C receptor antagonist SB 206553 in MC3T3-E1 cells, we believe that 
the fluoxetine effect could be direct on 5-HT2 receptors. The 5-HT2A receptor was expressed 
in MSC and NHO cells, and the expression seemed to be modulated by fluoxetine. Taken 
together, these data suggest that fluoxetine exerts its effects on proliferation of murine 
preosteoblasts, human MSC and primary osteoblasts via 5-HT2 receptors, however, species 
differences seem to exist.  
   We show that serotonin stimulated differentiation of human monocytes into osteoclasts. 
Addition of the 5-HT2A/2C receptor antagonist ketanserin inhibited serotonin induced 
differentiation in human osteoclasts suggesting that differentiation of monocytes into 
osteoclasts is partly mediated through the activation of the 5-HT2A/2C receptor.
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   Fluoxetine (1-3 ȝM) has been shown to reduce osteoclast differentiation in vitro (14). Our 
study confirmed that fluoxetine leads to a reduction in osteoclast differentiation and activity in 
μM concentrations, in the nM-ranges, however, osteoclast differentiation and activation 
seemed increased. Most pro- and anti-osteoclastogenic cytokines act primarily through the 
osteoblast to alter the levels of RANKL and OPG, the balance that determines overall 
osteoclast formation. The serotonin-induced augmentation of OPG and decrease of RANKL 
release found in the present study suggest a role in osteoblast-mediated inhibition of 
osteoclast generation. Fluoxetine reduced the OPG/RANKL ratio at all concentrations, 
indicating an osteoclastic mechanism in μM concentrations as well. No evidence of 
differences in resorptive indices in 5-HTT null mice was shown in vivo (15). If the fluoxetine 
effect on bone is direct through activation of serotonin receptors, the comparison with 5-HTT 
null mice is less relevant. Mice receiving fluoxetine, however, also had reduced bone mass 
but increased bone resorption at the distal femur was not shown (15). We found that 
fluoxetine in μM concentrations inhibited proliferation of MSCs and preosteoblasts, which 
may explain why fluoxetine treated mice, had a deficit in bone formation (15). 
   We demonstrate that both fluoxetine and serotonin activated NFțB activity in RAW264.7 
cells even in the absence of RANKL. Battaglino et al. have previously shown that serotonin 
stimulated, whereas fluoxetine had an inhibitory effect on NFțB activity in RAW264.7 cells 
(14). We found the effect to be dose-dependent and to vanish at higher concentrations for both 
compounds. The dose-dependent effect of fluoxetine and serotonin on osteoclast generation 
can thus be regulated via NFțB activation. We also found that the transcription factor cFos 
was positively involved in serotonin- and fluoxetine-induced effects on osteoclast formation.  
   Taken together, serotonin and fluoxetine may affect osteoblast and osteoclast formation 
both positively and negatively in vitro, via different mechanisms. Their effects are markedly 
concentration-dependent. In vivo serotonin and fluoxetine seem to have opposite effects on 
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BMD (8, 15). Despite the limitations of in vitro approaches (immortalized phenotype, clonal 
nature of cultures, and lack of circulating hormones), the current study presents possible 
mechanisms for the serotonin and fluoxetine induced bone alterations seen in vivo. Studies to 
determine the levels of serotonin and fluoxetine in bone marrow will be important to draw 
further conclusions from in vitro results. In vivo, under normal conditions, serotonergic 
mechanisms probably balance each other. Disruption of such a balance with serotonin 
interacting medications might interfere with normal bone metabolism. Medications interacting 
with the serotonergic system are becoming more and more common in clinical practice. 
SSRIs like fluoxetine are used in the treatment of depression and anxiety syndromes, 5-HT1A
receptor agonists in the treatment of migraine, while 5-HT3 receptor antagonists are used for 
chemotherapy-induced emesis. Recently, serotonin receptor interacting medications for 
treating irritable bowel syndrome also became available. These drugs are often prescribed for 
long periods of time. Little is known about the long-term effects on the skeleton using these 
medications and further investigation in this field is very important.  
   During the last years increasing interest has been directed against the bone modulating role 
of serotonin. Our data further underline that serotonin and its transporter exert important 
functions in bone remodeling.  
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            TABLE I 
Primer sets used in RT-PCR. 
Primers mRNA position                      Sequence                  Product length        Tann
mTph1 1370-1389 5’-AGTTGCGGTATGACCTTGAT-3’ 
1561-1543 5’-AGGCGAGAGACATTGCTAA-3’ 192 bp           60qC
h5-HT1A 1067-1086 5’-GCTGGCTGCCCTTCTT-3’ 
 1232-1213 5’-TTAAACGCGTTTTGAAAGTC-3’ 166 bp           54qC
h5-HT2A 1520-1538 5’-GACAATAGCGACGGAGTGA-3’
 1943-1923 5’-GGCAATAGGTAACCAACTCAA-3’     424 bp          54qC
h5-HT2A 917-936 5’-TCTTTCAGCTTCCTCCCTCA-3’  
 1139-1120 5’-TGCAGGACTCTTTGCAGATG-3’ 223 bp  58qC
h5-HT2B 1317-1336 5’-TGGCAGAGAACTCTAAGTTT-3’  
 1513-1493 5’-CTGCCAGTTCTGCTATACATA-3’ 197 bp           52qC
h5-HT2C 3638-3658 5’-ACGCTTGACAGTTACTTACAC-3’ 
 3906-3890 5’-GGCAAGGCAGGTAGACT-3’     269 bp           52qC
h5-HTT 2023-2038 5’-CTTGGGTTACTGCATAGGAAC-3’  
2181-2166  5’-GCATTCAAGCGGATGT-3’                   159 bp           52qC
hTph1         1057-1076 5’-CCCTTTGATCCCAAGATTAC-3’   
1267-1248  5’-CATTCATGGCACTGGTTATG-3’         211 bp           50qC
hCalcitonin 2535-2554 5’-CTTGTGGTTGACCGCTTGTT-3’   
receptor      2733-2714           5’-ATTTCAGGTGCCAGTAACGA-3’        199 b            58qC
M13Reverse         5’-CAGGAAACAGCTATGAC-3’                                    55qC
GAPDH   5’-TGCACCACCAACTGCTTAGC-3’ 
    5’-GGCATGGACTGTGGTCATGAG-3’                     60qC
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Figure 1. Gel electrophoresis of representative PCR products from one-step RT-PCR for 
serotonin receptors, 5-HTT and Tph1. (A) RT-PCR analysis of 5-HT1A (166 bp), 5-HT2A (424
bp), 5-HT2B (197 bp), 5-HT2C (269 bp), 5-HTT (159 bp), Tph1 (211 bp) and the calcitonin 
receptor (180 bp) expression in human PBMC cultured with RANKL and MCSF for 12 days. 
PCR reactions without reverse transcriptase (-RT) were used as negative controls (B) RT-
PCR analysis for mouse Tph1 (192 bp) expression in MC3T3-E1 cells and RAW264.7 cells at 
different differentiation stages. - RT was performed on a pool of RNA samples from MC3T3-
E1 or RAW264.7 cells respectively. The DNA ladder (L) was 100 bp.  
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Figure 2.  Serotonin and fluoxetine affect osteoclast differentiation and activation. (A) Human 
PBMC were cultured in medium with M-CSF and RANKL for 12 days in the presence of 
fluoxetine, (B) corresponding resorption pit assay. (C) An equivalent experiment with 
different serotonin concentrations and the 5-HT2A/C receptor antagonist ketanserin, (D) 
corresponding resorption pit assay. Data are presented as % of control (no addition) values. *p 
< 0.05. ¤Decrease in serotonin induced differentiation, p < 0.05.  
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Figure 3. Serotonin and fluoxetine enhance proliferation of murine preosteoclasts. (A) 
RAW264.7 cells treated with serotonin in different concentrations. (B) RAW264.7 cells 
treated with fluoxetine in different concentrations. Data are presented as % of control (no 
addition) values. *p < 0.05. 
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Figure 4. Fluoxetine and serotonin activate NFțB and cFos in RAW264.7 cells. (A) 
Fluoxetine (0.01 ȝM) and serotonin (0.01 ȝM) activate NFțB, at 10 ȝM however none of the 
compounds were effective. (B) Fluoxetine and serotonin induce cFos activation. *p < 0.05. 
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Figure 5. Serotonin stimulates osteoblast proliferation. (A) Proliferation assay on murine 
MC3T3-E1 cells treated with serotonin. (B) Assay on pFOSLuc transfected MC3T3-E1 cells 
given serotonin. (C) Proliferation assay on differentiated, human NHO cells and (D) human 
bone marrow stem cells (MSC). Data are presented as % of control (no addition) values. *p < 
0.05.
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Figure 6.  Effects of serotonin receptor and intracellular signaling pathway inhibition on 
serotonin induced proliferation of MC3T3-E1, preosteoblasts. (A) The PKC inhibitor GF 
109203 and to a lesser extent the PKA inhibitor H89 as well as the CAMK inhibitor W7 
inhibit serotonin induced proliferation. (B) The 5-HT2B/C receptor antagonist SB206553 and 
the 5-HT2A/C receptor antagonist ketanserin inhibit serotonin induced proliferation. Data are 
presented as % of control (no addition) values. *p < 0.05. 
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Figure 7. Effects of fluoxetine on proliferation in MC3T3-E1, NHO and MSC cells. (A) At 
lower concentrations fluoxetine seems to have a slight stimulating effect, whereas higher 
doses inhibit proliferation of MC3T3-E1 cells. (B) The effect of ketanserin (KET), SB 206553 
(SB) and serotonin (Ser) on fluoxetine (1 ȝM) induced inhibition of proliferation in MC3T3-
E1 cells. (C) The effect of fluoxetine alone and in combination with serotonin on NHO cell 
proliferation. ** indicates a significant reduction in fluoxetine induced proliferation, p < 0.05. 
(D) The effect of fluoxetine alone in combination with serotonin on MSC proliferation. Data 
are presented as % of control (no addition) values. *p < 0.05. 
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Figure 8. Serotonin and fluoxetine effects on RANKL and OPG release in MC3T3-E1 cells. 
(A) Inhibition of RANKL and (B) stimulation of OPG release by serotonin. (C) Stimulation 
of RANKL and (D) inhibition of OPG release by fluoxetine. Data are presented as % of 
control (no addition) values. *p < 0.05. 
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Microabstract
To investigate possible effects of serotonin on bone, rats were injected with serotonin 
s.c. for 3 months. BMD, femoral cortical thickness and stiffness were significantly 
higher in serotonin treated animals compared to controls. These findings show that 
serotonin affects bone metabolism, architecture and mechanical properties in vivo.
Abstract
Introduction: New evidence suggests a control of bone mass by the central nervous 
system. Many studies indicate a role for the nervous system in embryonic skeletal 
development, during fracture healing, and during remodeling after insertion of 
implants. We have previously shown that functional serotonin receptors are present in 
bone cells and that serotonin stimulates proliferation of osteoblast precursor cells in
vitro. In the present study we investigated the effects of serotonin on bone tissue in 
vivo.
Methods: Ten 2-month old female Sprague-Dawley rats were injected with serotonin 
subcutaneously (5mg/kg) once daily for 3 months. Controls received saline. Using 
microdialysis and HPLC, free circulating serotonin levels were measured. DXA scans 
were made after three months of serotonin administration . Bone architecture and 
mechanical properties were investigated by μCT, histomorphometry and mechanical 
testing.
Results: A long-lasting hyperserotoninemia with a >10-fold increase in serotonin 
appeared. Total body BMD was significantly higher (0.1976 ± 0.0015 vs. 0.1913 ± 
0.0012 g/cm2) in rats receiving serotonin. Cortical thickness measured by μCT 
analysis was also higher, whereas trabecular bone volume was lower. Interestingly, 
the perimeter and cross-sectional moment of inertia (MOI), a proxy for geometrical 
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bone strength, were the same in both groups. These data suggest that serotonin 
reduces resorption or increases apposition of endosteal bone. Mechanical testings 
showed that femoral stiffness was higher in serotonin dosed animals, while the energy 
absorption remained unchanged, indicating less deformation at fracture. As a result of 
a reduced body fat content (28.08 ± 7.20 vs. 42.96 ± 8.49 g), the body weight was 
lower in serotonin rats (305.5 ± 4.0 vs. 321.8 ± 5.3 g).
Conclusion: Hyperserotoninemia led to a higher BMD, altered bone architecture and 
changes in bone mechanical properties in growing rats, demonstrating that serotonin 
may have important effects on bone in vivo. 
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Introduction 
Skeletal remodeling is a highly regulated process that involves both formation and 
resorption of bone. Increasing interest has been directed towards peptide and amine 
hormones and their effects on bone cellular growth and differentiation. Studies on 
nerve terminals innervating bone have demonstrated the presence of several 
neuropeptides, including calcitonin gene related peptide (CGRP), vasoactive intestinal 
polypeptide (VIP), substance P, and neuropeptide Y.(1) Functional receptors for leptin 
and VIP have been demonstrated in osteoblasts and in osteoblastic cell lines.(2)
Serotonin (5-hydroxytryptamine or 5-HT) is a well-known amine neurotransmitter. 
Outside the central nervous system serotonin is mainly produced by the 
enterochromaffin cells of the gut and participates in the regulation of intestinal 
motility, fluid secretion and regional blood flow.(3) After release, serotonin is rapidly 
transported by the cell membrane bound serotonin transporter (5-HTT) into a number 
of cell types, with platelets serving as the major reservoir. Serotonin mediates its 
actions via multiple serotonin receptor subtypes.(4)  Until now seven serotonin receptor 
families (5-HT1-7)  have been characterised, and each is further divided into several 
subtypes. Studies on cell cultures have shown that serotonin has mitogenic effects on 
fibroblasts,(5) smooth muscle cells(6) and vascular endothelial cells(7) mediated through 
5-HT2 receptors. We recently demonstrated that long-term administration of high 
serotonin doses leads to a carcinoid heart like condition with myofibroblast 
proliferation and plaque formation on heart valves in rats.(8) In 2001 we were the first 
to demonstrate functional serotonin receptors in both osteoblasts and osteocytes.(9)
Furthermore, the expression of the serotonin transporter (5-HTT) has been 
demonstrated in rat osteoblasts and in osteoclasts.(10,11) Later we showed that 
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serotonin induced proliferation of osteoblasts and osteoclasts in vitro as well as 
increased BMD in rats in vivo.(12)
 As serotonin can affect bone cells via different mechanisms in vitro we 
hypothesized that it would also have effects on bone in vivo. In order to investigate 
the long-term impact of serotonin on BMD, architecture and mechanical properties we 
injected 2-month old female rats with serotonin subcutaneously (s.c.) daily for 3 
months, and then performed DXA scans, μCT, histomorphometry and mechanical 
testing.
Materials and methods 
Animals
The Animal Welfare Committee at Trondheim University Hospital approved this 
study. Twenty, 2-month old Sprague-Dawley female rats (200 g) were housed solely 
in wire-top cages with aspen woodchip bedding from B&K Universal Ltd. Room 
temperature was 24 ± 1°C with a relative humidity of 40 % to 50 % and a 12-hour 
light/dark cycle. The Rat and Mouse Diet of B&K and tap water were provided ad
libitum. Before all procedures (except for serotonin injections), the animals were 
anesthetized with 2 ml/kg body weight of a combination of fluanison (2.5 mg/ml), 
fentanyl (0.05 mg/ml), and midazolam (1.25 mg/ml). Serotonin (5-
Hydroxytryptamine Creatinin Sulfate Complex) purchased from Sigma-Aldrich was 
freshly dissolved in physiological saline (5 mg/ml) before injection. Ten rats were 
given daily serotonin injections s.c (5 mg/kg); 10 controls received saline. To avoid 
trauma and ulcers of the neck skin, the animals were immobilized in a specially built 
cage during the injections, which were given strictly subcutaneously with a 30-gauge 
BD syringe. At euthanization, the animals were weighed and decapitated. 
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In order to perform microdialysis, an additional experiment on 7 rats was carried out.  
Microdialysis 
To describe the pharmacokinetics of the serotonin administration protocol, a short-
term study on 7 animals was performed. Four animals were given daily serotonin 
injections (5 mg/kg s.c) for 10 days, 3 controls were given saline. Microdialysis was 
performed to determine the free fraction of circulating serotonin. We assumed that the 
interstitial serotonin level (collected from the femoral muscle) would reflect free 
circulating serotonin. Two hours before the final 10th serotonin injection, a 
microdialysis probe (CMA 20, 10 mm membrane length, 0.5 mm outer diameter, 20 
kDa cutoff; CMA Microdialysis AB, Stockholm, Sweden) was implanted in the 
femoral muscles. The microdialysis probes were perfused with PBS at a flow rate of 1 
μl min-1 using a microinfusion pump (CMA 107, CMA Microdialysis AB, Stockholm, 
Sweden). After a 30-minute equilibration period, baseline samples were collected for 
60-minutes. Then serotonin was injected s.c followed by microdialysate sampling in 
60-minute fractions for 5 hours. The samples were protected from light during the 
whole procedure and immediately frozen at -80°C until further analysis. In vitro
recovery of serotonin was 59.3 ± 3.2 % (mean ± SD).  
High-performance liquid chromatography (HPLC) 
The microdialysis samples were analyzed with an Agilent 1100 SL LC/MS-system 
consisting of  a G1354A quaternary pump with degasser, a G1367A well plate 
autosampler; a G1316A thermostatted column compartment and a G1956B single 
quadropol mass selective detector. Serotonin was monitored using selected ion 
monitoring on m/z 160. The samples were transferred to vials and added 10 % of the 
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sample with 1 % formic acid to stabilize serotonin. Fifteen ȝl of sample were injected 
on a 50 mm x 2.1mm Agilent Eclipse XDB-C18 with 1.8 micron particle size. The 
mobile phase was made up of 5 % Methanol and 95 % 25 mM of formic acid. 
Quantitation was done with external standard using the Agilent Chemstation software. 
The detection limit for serotonin in microdialysis samples was found to be 1.1 nM. 
Mean for a sample with theoretical value of 5 nM was 4.94 with a standard deviation 
of ± 0.32 nM. 
Double X-ray absorptiometry (DXA) measurements in vivo
The femur and total body BMD (g/cm2) were measured in anesthetized animals by 
means of DXA, using a Hologic QDR 4500A with a small animal software. BMD 
measurements were performed in duplicate at the start and end of the study. The 
coefficients of variation (CV) were: total body BMD (< 0.52 %), femur BMD (< 1.29 
%), area (<0.53 %), BMC (<0.55 %), body fat content (1.41 %) and lean body mass 
(0.20 %). 
Bone architecture 
Bone architecture was analyzed by means of micro-computed tomography (PCT)
scanning. Femoral head and part of the metaphysis (fig. 1) of the dissected femurs 
were scanned in a SkyScan 1072 microtomograph (SkyScan, Antwerp, Belgium), 
with a voxelsize of 11.89 Pm. Scans were processed, and three-dimensional 
morphometric analyses of the femurs were done using free software of the 3D-
Calculator Project (http://www.eur.nl/fgg/orthopaedics/Downloads.html). The data-
sets were separated in femoral head and metaphysis. In the metaphysis, cortical 
volume (Ct.V), and cortical thickness (Ct.Th) were measured. In the femoral head, 
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trabecular bone volume (BV), total bone marrow volume, including trabeculae (TV), 
trabecular bone volume fraction (BV/TV), trabecular thickness (Tb.Th),(13)
connectivity density (CD),(14) and structure model index (SMI) were determined.(15)
Cross-sectional moment of inertia (MOI) was determined over the complete data-set 
(femoral head + metaphysis). The mean of the periosteal perimeter was calculated for 
part of the metaphysis. 
Bone histomorphometry
In order to investigate bone resorption, Tartrate-Resistent Acid Phosphatase (TRAP) 
staining was used to stain osteoclasts, as described.(16) Eight sequential, longitudinal 
sections from each animal were used for TRAP stainings. To study bone formation, 
Goldner staining was performed to stain unmineralized matrix. 
Mechanical testing  
The left femurs were thawed in Ringers solution for mechanical testing of the 
diaphysis. The diaphyses were fractured 18.7 mm from the femoral condyles in three 
point cantilever bending as previously described.(17) The proximal femur was fixed in 
a clamp, the cam of the rotating wheel engaged the femoral condyles and a fulcrum 
positioned anteriorly 18.7 mm from the condyles was the third point of force 
application (Fig. 2) All tests were done at a loading rate of 0.095 radians/second (5.43 
degrees/second).(18) The load in the test apparatus, an MTS 858 Mini Bionix
Axial/Torsional Test System (MTS Systems Corporation, Minnesota, USA), was 
measured with a MTS Test Star TM Sensor Cartridge Force 250 N load cell and 
registered in MTS Test Star II software. 
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Ultimate moment, ultimate energy absorption, stiffness and deflection were read 
directly or calculated from the computer recordings. 
Statistical analysis
Data shown are expressed as means ± SEM. All data were tested for normality with 
Shapiro-Wilk. Normally distributed parameters were tested by means of Student’s T 
test, while parameters that were not normally distributed were tested by Mann-
Whitney U test. Significance was assumed at p values lower than 0.05.
Results
Serotonin measurements and clinical signs 
The serotonin injections induced clinical signs, including flushing, loose stools and 
drowsiness. The flushing and drowsiness lasted 3 - 4 hours after the injections. In 
dialysate collected from the femoral muscles, only one out of three control rats had a 
detectable serotonin (2.9 nM). In dialysate sampled 1 hour prior to the 10th injection, 
one out of four serotonin receiving animals had detectable serotonin (9.2 nM) in the 
femoral muscles. Two hours after the 10th injection, the serotonin level reached a peak 
(56.8 ± 9.6 nM) (Fig. 3). 
Body fat content and bone mineral density
An interesting finding was the weight-loss induced by serotonin. At the end of the 
study the serotonin treated animals weighed less than the controls (305.5 ± 4.0 vs. 
321.8 ± 5.3 g, p = 0.02). This was a result of a lower body fat content (28.08 ± 7.20 
vs. 42.96 ± 8.49 g, p = 0.0008), as the lean body mass remained unchanged (Fig. 4A-
B). Despite the lower body weight, the serotonin treated animals had higher total body 
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BMD (0.1976 ± 0.0015 vs. 0.1913 ± 0.0012 g/cm2, p = 0.004), while no difference 
was found in femoral BMD, compared to controls (Fig. 4C-D). The higher total body 
BMD in the serotonin group was a result of a lower bone area (52.99 ± 0.77 vs. 55.22 
± 0.76 cm2, p = 0.035), total body BMC, however, was not different compared to 
controls. No difference in body weight or parameters measured by DXA was 
observed between the groups at baseline. 
Bone architecture 
In the metaphysis, cortical thickness (Ct.Th) was significantly higher in the rats 
receiving serotonin versus controls (fig. 5A). On the other hand, trabecular bone 
volume (BV) as well as total bone marrow volume (TV) in the metaphysis were found 
to be significantly lower in the serotonin group compared to the control group (fig. 
5B-C). Trabecular bone volume fraction (BV/TV) (fig. 5D) and trabecular thickness 
(Tb.Th) remained unchanged, indicating that BV decreased due to a smaller TV. All 
other parameters studied were not significantly different in the metaphysis. In the 
femoral head no significant differences were found, although BV and TV showed the 
same trend as in the metaphysis. 
Bone histomorphometry 
All sections studied for TRAP staining were found to be negative (data not shown). 
Osteoclast activity may be very low, since bone turnover may already be low in rats 
of this age. Furthermore, no positive staining for unmineralized matrix was found in 
the sections (data not shown), which may also be due to a low bone turnover state or 
due to the fact that mineralization is known to occur very quickly in rodents. 
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Serotonin alters rat bone mechanical properties 
Consistent with the phenotypes of altered BMD and architecture, femurs from rats 
receiving serotonin had altered mechanical properties. In comparison with controls, 
mean stiffness of the femur in three-point bending was 12.3 % higher (Fig. 6). Bones 
from the serotonin rats tended to absorb more energy before breaking, but there was 
no statistical difference. There were no significant differences in ultimate bending 
moment or deflection in the femoral shaft. The lengths of the femurs were similar in 
the two groups. 
Discussion
We present here, for the first time, a study concerning long-term serotonin effects on 
bone in growing rats. In vitro studies have suggested that serotonin is a regulator of 
bone metabolism. The present work shows that serotonin has important in vivo effects 
on bone as well.
 Hormones like grehlin and leptin are involved in brain-gut regulation and 
recently they have been shown to have effects on bone metabolism and BMD.(19,20)
Serotonin found in the blood circulation is mainly produced by the enterochromaffin 
cells of the gut. More than 99 % of circulating serotonin is stored in platelet granules. 
As the free fraction of serotonin is believed to be biologically active, it is crucial to 
avoid platelet degranulation during blood sampling when serotonin measurements are 
to be done. We have previously demonstrated that sampling by microdialysis in 
femoral muscles gives a more accurate determination of the free fraction of 
circulating serotonin.(8) In this study we also used microdialysis combined with an 
improved HPLC technique to collect and analyze serotonin in femoral muscles. We 
found that the serotonin injections induced hyperserotoninemia, with a peak > 10 
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times higher than controls, 2 hours after the injection. The hyperserotoninemia lasted 
> 5 hours. 
A disturbance in central serotonin regulation has been implicated in eating and 
body weight disorders and drugs with affinity for serotonin receptors have been used 
in treatment of obesity.(21). Serotonin has been shown to reduce food intake and 
weight gain, and a role for hypothalamic serotonergic receptor mechanisms in 
mediation of these effects has been suggested.(22) In the present work we confirm that 
serotonin is a potent weight reducing substance, also when injected s.c. We also found 
that the low body weight was due to a reduced body fat content. 
Serotonin can reach bone cells and bone cell precursors via the blood 
circulation, but may also affect bone tissue via serotonergic neurons. The higher total 
body BMD (determined by DXA) that we find in serotonin dosed animals may 
therefore be mediated directly through serotonin receptors on cells involved in bone 
metabolism.(9,11) Although femur BMD measurements by means of DXA did not 
show significant changes, detailed high resolution μCT scans revealed that serotonin 
administration did affect bone architecture of the femur. Changes in the proximal 
head and the metaphysial region were similar, although they only reached significance 
in the metaphysis. This can be explained by the fact that normal bone turnover and 
adaptation of bone architecture are very high in the metaphysis of growing animals, 
making this region prone to react on drugs, chemicals and hormones. We found that 
moment of inertia and the perimeter of the metaphysis were unchanged, while cortical 
thickness was significantly higher in the serotonin group. On the other hand, we 
demonstrated that serotonin administration led to a lower trabecular bone volume, 
indicating that the effect of a higher cortical thickness is reversed by lower trabecular 
bone volume, resulting in similar moment of inertia in both groups. It is also possible 
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that there are changes in the distribution of trabecular bone in the marrow space that 
explains that there is no difference in MOI. For instance, the normal animals could 
have more trabecular bone close to the cortex while the serotonin animals have more 
evenly distributed trabecular bone. The unchanged trabecular bone volume fraction 
indicates that trabecular bone volume was lower solely because of a smaller total bone 
marrow volume. These results indicate that bone metabolism in the metaphysis of the 
femurs was affected by serotonin. Our hypothesis is that endosteal resorption was 
decreased during growth in rats receiving serotonin leading to higher cortical 
thickness, lower total bone marrow volume, and lower trabecular bone volume. This 
is in accordance with our in vitro findings showing an increased OPG/RANKL ratio 
(indicating an inhibitory effect on osteoclast activity) in medium collected from 
osteoblasts treated with serotonin (in press). The fact that no osteoclasts could be 
detected in the sections of both control as well as serotonin rats, does not exclude a 
difference in resorption at a given time point during serotonin administration. Another 
possible explanation for the changes seen in bone architecture could be that serotonin 
induces an increased endosteal bone apposition in growing rats, which could be 
explained by our previous findings showing that serotonin induces osteoblast 
proliferation in vitro.(12)
 Furthermore, we demonstrated that the stiffness of the femurs from the 
serotonin animals was increased while bone toughness remained unchanged. The 
increase in stiffness is probably due to the slightly enlarged cortical thickness, with 
more bone at the endosteal side. These results indicate less deflection and a slightly 
more brittle bone in the serotonin dosed animals. 
Serotonin is a regulator of craniofacial morphogenesis, and 5-HTT is present 
in developing craniofacial mesenchyme in mice where it is thought to influence the 
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morphogenetic effects of serotonin.(23) In a recent study, long-term administration of 
the 5-HTT inhibitor (selective serotonin reuptake inhibitor, SSRI) fluoxetine led to 
reduced bone accrual in growing mice.(24) Only a couple of reports on fracture risk 
and SSRI treatment have been published, and they suggest an increased fracture risk, 
even though the mechanism behind is unknown.(25-27) Another study demonstrated 
decreased growth in children during therapy with SSRI.(28) Taken together these 
studies indicate that serotonin is involved in bone development and bone turnover. 
This is the first in vivo study showing that serotonin administration affects bone 
metabolism in rats. Serotonergic mechanisms are highly preserved through evolution 
and species differences are small. It is therefore likely that changes similar to those 
seen in rats receiving serotonin would develop in humans with hyperserotoninemia. 
Further investigation is needed to understand the physiological role for serotonin in 
bone metabolism.  
In conclusion this study, for the first time, demonstrates that long-term 
serotonin administration leads to increased BMD, altered bone architecture and 
changes in mechanichal properties in growing rats.  
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FIG. 1.  A typical μCT-scan image. Areas for the separate data-sets of femoral head 
and metaphysis are depicted. 
20
FIG. 2.  Mechanical properties of the femoral midshaft were investigated using a 
three-point anterior bending test.
21
FIG. 3.  Serotonin levels in dialysate from femoral muscles in animals given daily 
subcutaneous serotonin injections (5 mg/kg) for 10 days. Dialysate was collected 1 
hour before and 5 hours after the 10th serotonin injection (Ĺ). Values are mean ± SEM;  
n = 4. 
22
FIG. 4.  Influence of long-term serotonin administration on body weight, fat content, 
BMD and bone area compared to controls. Results are shown as mean ± SD; n = 10. 
(A) Body weights were significantly lower in serotonin dosed animals compared to 
controls (ap = 0.02). (B) The body fat content was significantly lower (bp = 0.0008). 
(C) Total body BMD was significantly higher in the serotonin group (cp = 0.004). (D) 
Total body bone area was significantly lower in the serotonin group (dp = 0.035). 
23
FIG. 5. μCT scanning data of femoral head and metaphysis. Data are shown as 
means ± SEM; n = 10. (A) Cortical thickness [Ct.Th] is significantly higher in the 
metaphysis of serotonin dosed rats versus controls (ap = 0.009). (B) The serotonin 
dosed rats had significantly lower trabecular bone volume [BV] in the metaphysis (bp
= 0.035). (C) Total bone marrow volume [TV] was significantly lower in the 
metaphysis of serotonin dosed animals (cp = 0.002). (D) Trabecular bone volume 
fraction [BV/ TV] is similar in both groups. 
24
Fig. 6.   Femoral midshaft mechanical properties in control and serotonin dosed rats. 
(A) Energy absorption and (B) stiffness. aStatistically significantly higher compared 
to controls (p < 0.05). (C) Load-graph showing break point. Data are shown as means 
± SEM; n = 10. 
25



Dissertations at the Faculty of Medicine, NTNU
1977 
1. Knut Joachim Berg: EFFECT OF ACETYLSALICYLIC ACID ON RENAL FUNCTION 
2. Karl Erik Viken and Arne Ødegaard: STUDIES ON HUMAN MONOCYTES CULTURED IN
VITRO
1978 
3. Karel Bjørn Cyvin: CONGENITAL DISLOCATION OF THE HIP JOINT. 
4. Alf O. Brubakk: METHODS FOR STUDYING FLOW DYNAMICS IN THE LEFT 
VENTRICLE  AND THE AORTA IN MAN. 
1979 
5. Geirmund Unsgaard: CYTOSTATIC AND IMMUNOREGULATORY ABILITIES OF HUMAN    
BLOOD MONOCYTES CULTURED IN VITRO 
1980 
6. Størker Jørstad: URAEMIC TOXINS 
7. Arne Olav Jenssen: SOME RHEOLOGICAL, CHEMICAL AND STRUCTURAL PROPERTIES    
OF MUCOID SPUTUM FROM PATIENTS WITH CHRONIC OBSTRUCTIVE BRONCHITIS 
1981 
8. Jens Hammerstrøm: CYTOSTATIC AND CYTOLYTIC ACTIVITY OF HUMAN 
MONOCYTES AND EFFUSION MACROPHAGES AGAINST TUMOR CELLS IN VITRO 
1983 
9. Tore Syversen: EFFECTS OF METHYLMERCURY ON RAT BRAIN PROTEIN. 
10. Torbjørn Iversen: SQUAMOUS CELL CARCINOMA OF THE VULVA. 
1984 
11. Tor-Erik Widerøe: ASPECTS OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS. 
12. Anton Hole: ALTERATIONS OF MONOCYTE AND LYMPHOCYTE FUNCTIONS IN 
REALTION TO SURGERY UNDER EPIDURAL OR GENERAL ANAESTHESIA. 
13. Terje Terjesen: FRACTURE HEALING AN STRESS-PROTECTION AFTER METAL PLATE 
FIXATION AND EXTERNAL FIXATION. 
14. Carsten Saunte: CLUSTER HEADACHE SYNDROME. 
15. Inggard Lereim: TRAFFIC ACCIDENTS AND THEIR CONSEQUENCES. 
16. Bjørn Magne Eggen: STUDIES IN CYTOTOXICITY IN HUMAN ADHERENT 
MONONUCLEAR BLOOD CELLS. 
17. Trond Haug: FACTORS REGULATING BEHAVIORAL EFFECTS OG DRUGS. 
1985 
18. Sven Erik Gisvold: RESUSCITATION AFTER COMPLETE GLOBAL BRAIN ISCHEMIA. 
19. Terje Espevik: THE CYTOSKELETON OF HUMAN MONOCYTES. 
20. Lars Bevanger: STUDIES OF THE Ibc (c) PROTEIN ANTIGENS OF GROUP B 
STREPTOCOCCI.
21. Ole-Jan Iversen: RETROVIRUS-LIKE PARTICLES IN THE PATHOGENESIS OF PSORIASIS. 
22. Lasse Eriksen: EVALUATION AND TREATMENT OF ALCOHOL DEPENDENT 
BEHAVIOUR. 
23. Per I. Lundmo: ANDROGEN METABOLISM IN THE PROSTATE. 
1986 
24. Dagfinn Berntzen: ANALYSIS AND MANAGEMENT OF EXPERIMENTAL AND CLINICAL 
PAIN.
25. Odd Arnold Kildahl-Andersen: PRODUCTION AND CHARACTERIZATION OF 
MONOCYTE-DERIVED CYTOTOXIN AND ITS ROLE IN MONOCYTE-MEDIATED 
CYTOTOXICITY. 
26. Ola Dale: VOLATILE ANAESTHETICS. 
1987 
27. Per Martin Kleveland: STUDIES ON GASTRIN. 
28. Audun N. Øksendal: THE CALCIUM PARADOX AND THE HEART. 
29. Vilhjalmur R. Finsen: HIP FRACTURES 
1988 
30. Rigmor Austgulen: TUMOR NECROSIS FACTOR: A MONOCYTE-DERIVED REGULATOR 
OF CELLULAR GROWTH. 
31. Tom-Harald Edna: HEAD INJURIES ADMITTED TO HOSPITAL. 
32. Joseph D. Borsi: NEW ASPECTS OF THE CLINICAL PHARMACOKINETICS OF 
METHOTREXATE. 
33. Olav F. M. Sellevold: GLUCOCORTICOIDS IN MYOCARDIAL PROTECTION. 
34. Terje Skjærpe: NONINVASIVE QUANTITATION OF GLOBAL PARAMETERS ON LEFT 
VENTRICULAR FUNCTION: THE SYSTOLIC PULMONARY ARTERY PRESSURE AND 
CARDIAC OUTPUT. 
35. Eyvind Rødahl: STUDIES OF IMMUNE COMPLEXES AND RETROVIRUS-LIKE ANTIGENS 
IN PATIENTS WITH ANKYLOSING SPONDYLITIS. 
36. Ketil Thorstensen: STUDIES ON THE MECHANISMS OF CELLULAR UPTAKE OF IRON 
FROM TRANSFERRIN. 
37. Anna Midelfart: STUDIES OF THE MECHANISMS OF ION AND FLUID TRANSPORT IN 
THE BOVINE CORNEA. 
38. Eirik Helseth: GROWTH AND PLASMINOGEN ACTIVATOR ACTIVITY OF HUMAN 
GLIOMAS AND BRAIN METASTASES - WITH SPECIAL REFERENCE TO 
TRANSFORMING GROWTH FACTOR BETA AND THE EPIDERMAL GROWTH FACTOR 
RECEPTOR.
39. Petter C. Borchgrevink: MAGNESIUM AND THE ISCHEMIC HEART. 
40. Kjell-Arne Rein: THE EFFECT OF EXTRACORPOREAL CIRCULATION ON 
SUBCUTANEOUS TRANSCAPILLARY FLUID BALANCE. 
41. Arne Kristian Sandvik: RAT GASTRIC HISTAMINE. 
42. Carl Bredo Dahl: ANIMAL MODELS IN PSYCHIATRY. 
1989 
43. Torbjørn A. Fredriksen: CERVICOGENIC HEADACHE. 
44. Rolf A. Walstad: CEFTAZIDIME. 
45. Rolf Salvesen: THE PUPIL IN CLUSTER HEADACHE. 
46. Nils Petter Jørgensen: DRUG EXPOSURE IN EARLY PREGNANCY. 
47. Johan C. Ræder: PREMEDICATION AND GENERAL ANAESTHESIA IN OUTPATIENT 
GYNECOLOGICAL SURGERY. 
48. M. R. Shalaby: IMMUNOREGULATORY PROPERTIES OF TNF-D AND THE RELATED 
CYTOKINES. 
49. Anders Waage: THE COMPLEX PATTERN OF CYTOKINES IN SEPTIC SHOCK. 
50. Bjarne Christian Eriksen: ELECTROSTIMULATION OF THE PELVIC FLOOR IN FEMALE 
URINARY INCONTINENCE. 
51. Tore B. Halvorsen: PROGNOSTIC FACTORS IN COLORECTAL CANCER. 
1990 
52. Asbjørn Nordby: CELLULAR TOXICITY OF ROENTGEN CONTRAST MEDIA. 
53. Kåre E. Tvedt: X-RAY MICROANALYSIS OF BIOLOGICAL MATERIAL. 
54. Tore C. Stiles: COGNITIVE VULNERABILITY FACTORS IN THE DEVELOPMENT AND 
MAINTENANCE OF DEPRESSION. 
55. Eva Hofsli: TUMOR NECROSIS FACTOR AND MULTIDRUG RESISTANCE. 
56. Helge S. Haarstad: TROPHIC EFFECTS OF CHOLECYSTOKININ AND SECRETIN ON THE 
RAT PANCREAS. 
57. Lars Engebretsen: TREATMENT OF ACUTE ANTERIOR CRUCIATE LIGAMENT INJURIES. 
58. Tarjei Rygnestad: DELIBERATE SELF-POISONING IN TRONDHEIM. 
59. Arne Z. Henriksen: STUDIES ON CONSERVED ANTIGENIC DOMAINS ON MAJOR OUTER 
MEMBRANE PROTEINS FROM ENTEROBACTERIA. 
60. Steinar Westin: UNEMPLOYMENT AND HEALTH: Medical and social consequences of a 
factory closure in a ten-year controlled follow-up study. 
61. Ylva Sahlin: INJURY REGISTRATION, a tool for accident preventive work. 
62. Helge Bjørnstad Pettersen: BIOSYNTHESIS OF COMPLEMENT BY HUMAN ALVEOLAR 
MACROPHAGES WITH SPECIAL REFERENCE TO SARCOIDOSIS. 
63. Berit Schei: TRAPPED IN PAINFUL LOVE. 
64. Lars J. Vatten: PROSPECTIVE STUDIES OF THE RISK OF BREAST CANCER IN A 
COHORT OF NORWEGIAN WOMAN. 
1991 
65. Kåre Bergh: APPLICATIONS OF ANTI-C5a SPECIFIC MONOCLONAL ANTIBODIES FOR 
THE ASSESSMENT OF COMPLEMENT ACTIVATION. 
66. Svein Svenningsen: THE CLINICAL SIGNIFICANCE OF INCREASED FEMORAL 
ANTEVERSION. 
67. Olbjørn Klepp: NONSEMINOMATOUS GERM CELL TESTIS CANCER: THERAPEUTIC 
OUTCOME AND PROGNOSTIC FACTORS. 
68. Trond Sand: THE EFFECTS OF CLICK POLARITY ON BRAINSTEM AUDITORY EVOKED 
POTENTIALS AMPLITUDE, DISPERSION, AND LATENCY VARIABLES. 
69. Kjetil B. Åsbakk: STUDIES OF A PROTEIN FROM PSORIATIC SCALE, PSO P27, WITH 
RESPECT TO ITS POTENTIAL ROLE IN IMMUNE REACTIONS IN PSORIASIS. 
70. Arnulf Hestnes: STUDIES ON DOWN´S SYNDROME. 
71. Randi Nygaard: LONG-TERM SURVIVAL IN CHILDHOOD LEUKEMIA. 
72. Bjørn Hagen: THIO-TEPA. 
73. Svein Anda: EVALUATION OF THE HIP JOINT BY COMPUTED TOMOGRAMPHY AND 
ULTRASONOGRAPHY. 
1992 
74. Martin Svartberg: AN INVESTIGATION OF PROCESS AND OUTCOME OF SHORT-TERM 
PSYCHODYNAMIC PSYCHOTHERAPY. 
75. Stig Arild Slørdahl: AORTIC REGURGITATION. 
76. Harold C Sexton: STUDIES RELATING TO THE TREATMENT OF SYMPTOMATIC NON-
PSYCHOTIC PATIENTS. 
77. Maurice B. Vincent: VASOACTIVE PEPTIDES IN THE OCULAR/FOREHEAD AREA. 
78. Terje Johannessen: CONTROLLED TRIALS IN SINGLE SUBJECTS. 
79. Turid Nilsen: PYROPHOSPHATE IN HEPATOCYTE IRON METABOLISM. 
80. Olav Haraldseth: NMR SPECTROSCOPY OF CEREBRAL ISCHEMIA AND REPERFUSION 
IN RAT. 
81. Eiliv Brenna: REGULATION OF FUNCTION AND GROWTH OF THE OXYNTIC MUCOSA. 
1993 
82. Gunnar Bovim: CERVICOGENIC HEADACHE. 
83. Jarl Arne Kahn: ASSISTED PROCREATION. 
84. Bjørn Naume: IMMUNOREGULATORY EFFECTS OF CYTOKINES ON NK CELLS. 
85. Rune Wiseth: AORTIC VALVE REPLACEMENT. 
86. Jie Ming Shen: BLOOD FLOW VELOCITY AND RESPIRATORY STUDIES. 
87. Piotr Kruszewski: SUNCT SYNDROME WITH SPECIAL REFERENCE TO THE 
AUTONOMIC NERVOUS SYSTEM. 
88. Mette Haase Moen: ENDOMETRIOSIS. 
89. Anne Vik: VASCULAR GAS EMBOLISM DURING AIR INFUSION AND AFTER 
DECOMPRESSION IN PIGS. 
90. Lars Jacob Stovner: THE CHIARI TYPE I MALFORMATION. 
91. Kjell Å. Salvesen: ROUTINE ULTRASONOGRAPHY IN UTERO AND DEVELOPMENT IN 
CHILDHOOD. 
1994 
92. Nina-Beate Liabakk: DEVELOPMENT OF IMMUNOASSAYS FOR TNF AND ITS SOLUBLE 
RECEPTORS.
93. Sverre Helge Torp: erbB ONCOGENES IN HUMAN GLIOMAS AND MENINGIOMAS. 
94. Olav M. Linaker: MENTAL RETARDATION AND PSYCHIATRY. Past and present. 
95. Per Oscar Feet: INCREASED ANTIDEPRESSANT AND ANTIPANIC EFFECT IN 
COMBINED TREATMENT WITH DIXYRAZINE AND TRICYCLIC ANTIDEPRESSANTS. 
96. Stein Olav Samstad: CROSS SECTIONAL FLOW VELOCITY PROFILES FROM TWO-
DIMENSIONAL DOPPLER ULTRASOUND: Studies on early mitral blood flow. 
97. Bjørn Backe: STUDIES IN ANTENATAL CARE. 
98. Gerd Inger Ringdal: QUALITY OF LIFE IN CANCER PATIENTS. 
99. Torvid Kiserud: THE DUCTUS VENOSUS IN THE HUMAN FETUS. 
100.Hans E. Fjøsne: HORMONAL REGULATION OF PROSTATIC METABOLISM. 
101.Eylert Brodtkorb: CLINICAL ASPECTS OF EPILEPSY IN THE MENTALLY RETARDED. 
102.Roar Juul: PEPTIDERGIC MECHANISMS IN HUMAN SUBARACHNOID HEMORRHAGE. 
103.Unni Syversen: CHROMOGRANIN A. Phsysiological and Clinical Role. 
1995 
104.Odd Gunnar Brakstad: THERMOSTABLE NUCLEASE AND THE nuc GENE IN THE 
DIAGNOSIS OF Staphylococcus aureus INFECTIONS. 
105.Terje Engan: NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY OF PLASMA 
IN MALIGNANT DISEASE. 
106.Kirsten Rasmussen: VIOLENCE IN THE MENTALLY DISORDERED. 
107.Finn Egil Skjeldestad: INDUCED ABORTION: Timetrends and Determinants. 
108.Roar Stenseth: THORACIC EPIDURAL ANALGESIA IN AORTOCORONARY BYPASS 
SURGERY.
109.Arild Faxvaag: STUDIES OF IMMUNE CELL FUNCTION in mice infected with MURINE 
RETROVIRUS.
1996 
110.Svend Aakhus: NONINVASIVE COMPUTERIZED ASSESSMENT OF LEFT VENTRICULAR 
FUNCTION AND SYSTEMIC ARTERIAL PROPERTIES. Methodology and some clinical 
applications. 
111.Klaus-Dieter Bolz: INTRAVASCULAR ULTRASONOGRAPHY. 
112.Petter Aadahl: CARDIOVASCULAR EFFECTS OF THORACIC AORTIC CROSS-
CLAMPING.
113.Sigurd Steinshamn: CYTOKINE MEDIATORS DURING GRANULOCYTOPENIC 
INFECTIONS. 
114.Hans Stifoss-Hanssen: SEEKING MEANING OR HAPPINESS? 
115.Anne Kvikstad: LIFE CHANGE EVENTS AND MARITAL STATUS IN RELATION TO RISK 
AND PROGNOSIS OF CANSER. 
116.Torbjørn Grøntvedt: TREATMENT OF ACUTE AND CHRONIC ANTERIOR CRUCIATE 
LIGAMENT INJURIES. A clinical and biomechanical study. 
117.Sigrid Hørven Wigers: CLINICAL STUDIES OF FIBROMYALGIA WITH FOCUS ON 
ETIOLOGY, TREATMENT AND OUTCOME. 
118.Jan Schjøtt: MYOCARDIAL PROTECTION: Functional and Metabolic Characteristics of Two 
Endogenous Protective Principles. 
119.Marit Martinussen: STUDIES OF INTESTINAL BLOOD FLOW AND ITS RELATION TO 
TRANSITIONAL CIRCULATORY ADAPATION IN NEWBORN INFANTS. 
120.Tomm B. Müller: MAGNETIC RESONANCE IMAGING IN FOCAL CEREBRAL ISCHEMIA. 
121.Rune Haaverstad: OEDEMA FORMATION OF THE LOWER EXTREMITIES. 
122.Magne Børset: THE ROLE OF CYTOKINES IN MULTIPLE MYELOMA, WITH SPECIAL 
REFERENCE TO HEPATOCYTE GROWTH FACTOR. 
123.Geir Smedslund: A THEORETICAL AND EMPIRICAL INVESTIGATION OF SMOKING, 
STRESS AND DISEASE: RESULTS FROM A POPULATION SURVEY. 
1997 
124.Torstein Vik: GROWTH, MORBIDITY, AND PSYCHOMOTOR DEVELOPMENT IN 
INFANTS WHO WERE GROWTH RETARDED IN UTERO.
125.Siri Forsmo: ASPECTS AND CONSEQUENCES OF OPPORTUNISTIC SCREENING FOR 
CERVICAL CANCER. Results based on data from three Norwegian counties. 
126.Jon S. Skranes: CEREBRAL MRI AND NEURODEVELOPMENTAL OUTCOME IN VERY 
LOW BIRTH WEIGHT (VLBW) CHILDREN. A follow-up study of a geographically based year 
cohort of VLBW children at ages one and six years. 
127.Knut Bjørnstad: COMPUTERIZED ECHOCARDIOGRAPHY FOR EVALUTION OF 
CORONARY ARTERY DISEASE. 
128.Grethe Elisabeth Borchgrevink: DIAGNOSIS AND TREATMENT OF WHIPLASH/NECK 
SPRAIN INJURIES CAUSED BY CAR ACCIDENTS. 
129.Tor Elsås: NEUROPEPTIDES AND NITRIC OXIDE SYNTHASE IN OCULAR AUTONOMIC 
AND SENSORY NERVES. 
130.Rolf W. Gråwe: EPIDEMIOLOGICAL AND NEUROPSYCHOLOGICAL PERSPECTIVES ON 
SCHIZOPHRENIA. 
131.Tonje Strømholm: CEREBRAL HAEMODYNAMICS DURING THORACIC AORTIC 
CROSSCLAMPING. An experimental study in pigs. 
1998 
132.Martinus Bråten: STUDIES ON SOME PROBLEMS REALTED TO INTRAMEDULLARY 
NAILING OF FEMORAL FRACTURES. 
133.Ståle Nordgård: PROLIFERATIVE ACTIVITY AND DNA CONTENT AS PROGNOSTIC 
INDICATORS IN ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK. 
134.Egil Lien: SOLUBLE RECEPTORS FOR TNF AND LPS: RELEASE PATTERN AND 
POSSIBLE SIGNIFICANCE IN DISEASE. 
135.Marit Bjørgaas: HYPOGLYCAEMIA IN CHILDREN WITH DIABETES MELLITUS 
136.Frank Skorpen: GENETIC AND FUNCTIONAL ANALYSES OF DNA REPAIR IN HUMAN 
CELLS.
137.Juan A. Pareja: SUNCT SYNDROME. ON THE CLINICAL PICTURE. ITS DISTINCTION 
FROM OTHER, SIMILAR HEADACHES. 
138.Anders Angelsen: NEUROENDOCRINE CELLS IN HUMAN PROSTATIC CARCINOMAS 
AND THE PROSTATIC COMPLEX OF RAT, GUINEA PIG, CAT AND DOG. 
139.Fabio Antonaci: CHRONIC  PAROXYSMAL HEMICRANIA AND HEMICRANIA 
CONTINUA: TWO DIFFERENT ENTITIES? 
140.Sven M. Carlsen: ENDOCRINE AND METABOLIC EFFECTS OF METFORMIN WITH 
SPECIAL EMPHASIS ON CARDIOVASCULAR RISK FACTORES. 
1999 
141.Terje A. Murberg: DEPRESSIVE SYMPTOMS AND COPING AMONG PATIENTS WITH 
CONGESTIVE HEART FAILURE. 
142.Harm-Gerd Karl Blaas: THE EMBRYONIC EXAMINATION. Ultrasound studies on the 
development of the human embryo. 
143.Noèmi Becser Andersen:THE CEPHALIC SENSORY NERVES IN UNILATERAL 
HEADACHES. Anatomical background and neurophysiological evaluation. 
144.Eli-Janne Fiskerstrand: LASER TREATMENT OF PORT WINE STAINS. A study of the efficacy 
and limitations of the pulsed dye laser. Clinical and morfological analyses aimed at improving the 
therapeutic outcome. 
145.Bård Kulseng: A STUDY OF ALGINATE CAPSULE PROPERTIES AND CYTOKINES IN 
RELATION TO INSULIN DEPENDENT DIABETES MELLITUS. 
146.Terje Haug: STRUCTURE AND REGULATION OF THE HUMAN UNG GENE ENCODING 
URACIL-DNA GLYCOSYLASE. 
147.Heidi Brurok: MANGANESE AND THE HEART. A Magic Metal with Diagnostic and 
Therapeutic Possibilites. 
148.Agnes Kathrine Lie: DIAGNOSIS AND PREVALENCE OF HUMAN PAPILLOMAVIRUS 
INFECTION IN CERVICAL INTRAEPITELIAL NEOPLASIA. Relationship to Cell Cycle 
Regulatory Proteins and HLA DQBI Genes. 
149.Ronald Mårvik: PHARMACOLOGICAL, PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL 
STUDIES ON ISOLATED STOMACS. 
150.Ketil Jarl Holen: THE ROLE OF ULTRASONOGRAPHY IN THE DIAGNOSIS AND 
TREATMENT OF HIP DYSPLASIA IN NEWBORNS. 
151.Irene Hetlevik:  THE ROLE OF CLINICAL GUIDELINES IN CARDIOVASCULAR RISK 
INTERVENTION IN GENERAL PRACTICE. 
152.Katarina Tunòn: ULTRASOUND AND PREDICTION OF GESTATIONAL AGE. 
153.Johannes Soma: INTERACTION BETWEEN THE LEFT VENTRICLE AND THE SYSTEMIC 
ARTERIES. 
154.Arild Aamodt: DEVELOPMENT AND PRE-CLINICAL EVALUATION OF A CUSTOM-
MADE FEMORAL STEM. 
155.Agnar Tegnander: DIAGNOSIS AND FOLLOW-UP OF CHILDREN WITH SUSPECTED OR 
KNOWN HIP DYSPLASIA. 
156.Bent Indredavik: STROKE UNIT TREATMENT: SHORT AND LONG-TERM EFFECTS 
157.Jolanta Vanagaite Vingen: PHOTOPHOBIA AND PHONOPHOBIA IN PRIMARY 
HEADACHES 
2000 
158.Ola Dalsegg Sæther: PATHOPHYSIOLOGY DURING PROXIMAL AORTIC CROSS-
CLAMPING
159.CLINICAL AND EXPERIMENTAL STUDIES 
160.Christina Vogt Isaksen: PRENATAL ULTRASOUND AND POSTMORTEM FINDINGS – A 
TEN YEAR CORRELATIVE STUDY OF FETUSES AND INFANTS WITH 
DEVELOPMENTAL ANOMALIES. 
161.Holger Seidel: HIGH-DOSE METHOTREXATE THERAPY IN CHILDREN WITH ACUTE 
LYMPHOCYTIC LEUKEMIA: DOSE, CONCENTRATION, AND EFFECT 
CONSIDERATIONS. 
162.Stein Hallan: IMPLEMENTATION OF MODERN MEDICAL DECISION ANALYSIS INTO 
CLINICAL DIAGNOSIS AND TREATMENT. 
163.Malcolm Sue-Chu: INVASIVE AND NON-INVASIVE STUDIES IN CROSS-COUNTRY 
SKIERS WITH ASTHMA-LIKE SYMPTOMS. 
164.Ole-Lars Brekke: EFFECTS OF ANTIOXIDANTS AND FATTY ACIDS ON TUMOR 
NECROSIS FACTOR-INDUCED CYTOTOXICITY. 
165.Jan Lundbom: AORTOCORONARY BYPASS SURGERY: CLINICAL ASPECTS, COST 
CONSIDERATIONS AND WORKING ABILITY. 
166.John-Anker Zwart: LUMBAR NERVE ROOT COMPRESSION, BIOCHEMICAL AND 
NEUROPHYSIOLOGICAL ASPECTS. 
167.Geir Falck: HYPEROSMOLALITY AND THE HEART. 
168.Eirik Skogvoll: CARDIAC ARREST Incidence, Intervention and Outcome. 
169.Dalius Bansevicius: SHOULDER-NECK REGION IN CERTAIN HEADACHES AND 
CHRONIC PAIN SYNDROMES. 
170.Bettina Kinge: REFRACTIVE ERRORS AND BIOMETRIC CHANGES AMONG 
UNIVERSITY STUDENTS IN NORWAY. 
171.Gunnar Qvigstad: CONSEQUENCES OF HYPERGASTRINEMIA IN MAN 
172.Hanne Ellekjær: EPIDEMIOLOGICAL STUDIES OF STROKE IN A NORWEGIAN 
POPULATION. INCIDENCE, RISK FACTORS AND PROGNOSIS 
173.Hilde Grimstad: VIOLENCE AGAINST WOMEN AND PREGNANCY OUTCOME. 
174.Astrid Hjelde: SURFACE TENSION AND COMPLEMENT ACTIVATION: Factors influencing 
bubble formation and bubble effects after decompression. 
175.Kjell A. Kvistad: MR IN BREAST CANCER – A CLINICAL STUDY. 
176.Ivar Rossvoll: ELECTIVE ORTHOPAEDIC SURGERY IN A DEFINED POPULATION. Studies 
on demand, waiting time for treatment and incapacity for work. 
177.Carina Seidel: PROGNOSTIC VALUE AND BIOLOGICAL EFFECTS OF HEPATOCYTE 
GROWTH FACTOR AND SYNDECAN-1 IN MULTIPLE MYELOMA. 
2001 
178.Alexander Wahba: THE INFLUENCE OF CARDIOPULMONARY BYPASS ON PLATELET 
FUNCTION AND BLOOD COAGULATION – DETERMINANTS AND CLINICAL 
CONSEQUENSES 
179.Marcus Schmitt-Egenolf: THE RELEVANCE OF THE MAJOR hISTOCOMPATIBILITY 
COMPLEX FOR THE GENETICS OF PSORIASIS 
180.Odrun Arna Gederaas: BIOLOGICAL MECHANISMS INVOLVED IN 5-AMINOLEVULINIC 
ACID BASED PHOTODYNAMIC THERAPY 
181.Pål Richard Romundstad: CANCER INCIDENCE AMONG NORWEGIAN ALUMINIUM 
WORKERS 
182.Henrik Hjorth-Hansen: NOVEL CYTOKINES IN GROWTH CONTROL AND BONE DISEASE 
OF MULTIPLE MYELOMA 
183.Gunnar Morken: SEASONAL VARIATION OF HUMAN MOOD AND BEHAVIOUR 
184.Bjørn Olav Haugen: MEASUREMENT OF CARDIAC OUTPUT AND STUDIES OF 
VELOCITY PROFILES IN AORTIC AND MITRAL FLOW USING TWO- AND THREE-
DIMENSIONAL COLOUR FLOW IMAGING 
185.Geir Bråthen: THE CLASSIFICATION AND CLINICAL DIAGNOSIS OF ALCOHOL-
RELATED SEIZURES 
186.Knut Ivar Aasarød: RENAL INVOLVEMENT IN INFLAMMATORY RHEUMATIC DISEASE. 
A Study of Renal Disease in Wegener’s Granulomatosis and in Primary Sjögren’s Syndrome  
187.Trude Helen Flo: RESEPTORS INVOLVED IN CELL ACTIVATION BY DEFINED URONIC 
ACID POLYMERS AND BACTERIAL COMPONENTS 
188.Bodil Kavli: HUMAN URACIL-DNA GLYCOSYLASES FROM THE UNG GENE: 
STRUCTRUAL BASIS FOR SUBSTRATE SPECIFICITY AND REPAIR 
189.Liv Thommesen: MOLECULAR MECHANISMS INVOLVED IN TNF- AND GASTRIN-
MEDIATED GENE REGULATION 
190.Turid Lingaas Holmen: SMOKING AND HEALTH IN ADOLESCENCE; THE NORD-
TRØNDELAG HEALTH STUDY, 1995-97 
191.Øyvind Hjertner: MULTIPLE MYELOMA: INTERACTIONS BETWEEN MALIGNANT 
PLASMA CELLS AND THE BONE MICROENVIRONMENT 
192.Asbjørn Støylen: STRAIN RATE IMAGING OF THE LEFT VENTRICLE BY ULTRASOUND. 
FEASIBILITY, CLINICAL VALIDATION AND PHYSIOLOGICAL ASPECTS 
193.Kristian Midthjell: DIABETES IN ADULTS IN NORD-TRØNDELAG. PUBLIC HEALTH 
ASPECTS OF DIABETES MELLITUS IN A LARGE, NON-SELECTED NORWEGIAN 
POPULATION. 
194.Guanglin Cui: FUNCTIONAL ASPECTS OF THE ECL CELL IN RODENTS 
195.Ulrik Wisløff: CARDIAC EFFECTS OF AEROBIC ENDURANCE TRAINING: 
HYPERTROPHY, CONTRACTILITY AND CALCUIM HANDLING IN NORMAL AND 
FAILING HEART 
196.Øyvind Halaas: MECHANISMS OF IMMUNOMODULATION AND CELL-MEDIATED 
CYTOTOXICITY INDUCED BY BACTERIAL PRODUCTS 
197.Tore Amundsen: PERFUSION MR IMAGING IN THE DIAGNOSIS OF PULMONARY 
EMBOLISM
198.Nanna Kurtze: THE SIGNIFICANCE OF ANXIETY AND DEPRESSION IN FATIQUE AND 
PATTERNS OF PAIN AMONG INDIVIDUALS DIAGNOSED WITH FIBROMYALGIA: 
RELATIONS WITH QUALITY OF LIFE, FUNCTIONAL DISABILITY, LIFESTYLE, 
EMPLOYMENT STATUS, CO-MORBIDITY AND GENDER 
199.Tom Ivar Lund Nilsen: PROSPECTIVE STUDIES OF CANCER RISK IN NORD-
TRØNDELAG: THE HUNT STUDY. Associations with anthropometric, socioeconomic, and 
lifestyle risk factors 
200.Asta Kristine Håberg: A NEW APPROACH TO THE STUDY OF MIDDLE CEREBRAL 
ARTERY OCCLUSION IN THE RAT USING MAGNETIC RESONANCE TECHNIQUES 
2002 
201.Knut Jørgen Arntzen: PREGNANCY AND CYTOKINES 
202.Henrik Døllner: INFLAMMATORY MEDIATORS IN PERINATAL INFECTIONS 
203.Asta Bye: LOW FAT, LOW LACTOSE DIET USED AS PROPHYLACTIC TREATMENT OF 
ACUTE INTESTINAL REACTIONS DURING PELVIC RADIOTHERAPY. A PROSPECTIVE 
RANDOMISED STUDY. 
204.Sylvester Moyo: STUDIES ON STREPTOCOCCUS AGALACTIAE  (GROUP B 
STREPTOCOCCUS) SURFACE-ANCHORED MARKERS WITH EMPHASIS ON STRAINS 
AND HUMAN SERA FROM ZIMBABWE. 
205.Knut Hagen: HEAD-HUNT: THE EPIDEMIOLOGY OF HEADACHE IN NORD-TRØNDELAG 
206.Li Lixin: ON THE REGULATION AND ROLE OF UNCOUPLING PROTEIN-2 IN INSULIN 
PRODUCING ß-CELLS 
207.Anne Hildur Henriksen: SYMPTOMS OF ALLERGY AND ASTHMA VERSUS MARKERS OF 
LOWER AIRWAY INFLAMMATION AMONG ADOLESCENTS 
208.Egil Andreas Fors: NON-MALIGNANT PAIN IN RELATION TO PSYCHOLOGICAL AND 
ENVIRONTENTAL FACTORS. EXPERIENTAL AND CLINICAL STUDES OF PAIN WITH 
FOCUS ON FIBROMYALGIA 
209.Pål Klepstad:  MORPHINE FOR CANCER PAIN 
210.Ingunn Bakke: MECHANISMS AND CONSEQUENCES OF PEROXISOME PROLIFERATOR-
INDUCED HYPERFUNCTION OF THE RAT GASTRIN PRODUCING CELL 
211.Ingrid Susann Gribbestad: MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY OF 
BREAST CANCER 
212.Rønnaug Astri Ødegård: PREECLAMPSIA – MATERNAL RISK FACTORS AND FETAL 
GROWTH 
213.Johan Haux: STUDIES ON CYTOTOXICITY INDUCED BY HUMAN NATURAL KILLER 
CELLS AND DIGITOXIN 
214.Turid Suzanne Berg-Nielsen: PARENTING PRACTICES AND MENTALLY DISORDERED 
ADOLESCENTS 
215.Astrid Rydning: BLOOD FLOW AS A PROTECTIVE FACTOR FOR THE STOMACH 
MUCOSA. AN EXPERIMENTAL STUDY ON THE ROLE OF MAST CELLS AND SENSORY 
AFFERENT NEURONS 
2003 
216.Jan Pål Loennechen: HEART FAILURE AFTER MYOCARDIAL INFARCTION. Regional 
Differences, Myocyte Function, Gene Expression, and Response to Cariporide, Losartan, and 
Exercise Training. 
217.Elisabeth Qvigstad: EFFECTS OF FATTY ACIDS AND OVER-STIMULATION ON INSULIN 
SECRETION IN MAN 
218.Arne Åsberg: EPIDEMIOLOGICAL STUDIES IN HEREDITARY HEMOCHROMATOSIS: 
PREVALENCE, MORBIDITY AND BENEFIT OF SCREENING. 
219.Johan Fredrik Skomsvoll: REPRODUCTIVE OUTCOME IN WOMEN WITH RHEUMATIC 
DISEASE. A population registry based study of the effects of inflammatory rheumatic disease and 
connective tissue disease on reproductive outcome in Norwegian women in 1967-1995. 
220.Siv Mørkved: URINARY INCONTINENCE DURING PREGNANCY AND AFTER  
DELIVERY: EFFECT OF PELVIC FLOOR MUSCLE TRAINING IN PREVENTION AND 
TREATMENT 
221.Marit S. Jordhøy: THE IMPACT OF COMPREHENSIVE PALLIATIVE CARE 
222.Tom Christian Martinsen: HYPERGASTRINEMIA AND HYPOACIDITY IN RODENTS – 
CAUSES AND CONSEQUENCES  
223.Solveig Tingulstad: CENTRALIZATION OF PRIMARY SURGERY FOR OVARAIN CANCER. 
FEASIBILITY AND IMPACT ON SURVIVAL  
224.Haytham Eloqayli: METABOLIC CHANGES IN THE BRAIN CAUSED BY EPILEPTIC 
SEIZURES 
225.Torunn Bruland: STUDIES OF EARLY RETROVIRUS-HOST INTERACTIONS – VIRAL 
DETERMINANTS FOR PATHOGENESIS AND THE INFLUENCE OF SEX ON THE 
SUSCEPTIBILITY TO FRIEND MURINE LEUKAEMIA VIRUS INFECTION 
226.Torstein Hole: DOPPLER ECHOCARDIOGRAPHIC EVALUATION OF LEFT 
VENTRICULAR FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
227.Vibeke Nossum: THE EFFECT OF VASCULAR BUBBLES ON ENDOTHELIAL FUNCTION 
228.Sigurd Fasting: ROUTINE BASED RECORDING OF ADVERSE EVENTS DURING 
ANAESTHESIA – APPLICATION IN QUALITY IMPROVEMENT AND SAFETY 
229.Solfrid Romundstad: EPIDEMIOLOGICAL STUDIES OF MICROALBUMINURIA. THE 
NORD-TRØNDELAG HEALTH STUDY 1995-97 (HUNT 2) 
230.Geir Torheim: PROCESSING OF DYNAMIC DATA SETS IN MAGNETIC RESONANCE 
IMAGING 
231.Catrine Ahlén: SKIN INFECTIONS IN OCCUPATIONAL SATURATION DIVERS IN THE 
NORTH SEA AND THE IMPACT OF THE ENVIRONMENT 
232.Arnulf Langhammer: RESPIRATORY SYMPTOMS, LUNG FUNCTION AND BONE 
MINERAL DENSITY IN A COMPREHENSIVE POPULATION SURVEY. THE NORD-
TRØNDELAG HEALTH STUDY 1995-97. THE BRONCHIAL OBSTRUCTION IN NORD-
TRØNDELAG STUDY 
233.Einar Kjelsås: EATING DISORDERS AND PHYSICAL ACTIVITY IN NON-CLINICAL 
SAMPLES 
234.Arne Wibe: RECTAL CANCER TREATMENT IN NORWAY – STANDARDISATION OF 
SURGERY AND QUALITY ASSURANCE 
2004 
235.Eivind Witsø: BONE GRAFT AS AN ANTIBIOTIC CARRIER 
236.Anne Mari Sund: DEVELOPMENT OF DEPRESSIVE SYMPTOMS IN EARLY 
ADOLESCENCE   
237.Hallvard Lærum: EVALUATION OF ELECTRONIC MEDICAL RECORDS – A CLINICAL 
TASK PERSPECTIVE  
238.Gustav Mikkelsen: ACCESSIBILITY OF INFORMATION IN ELECTRONIC PATIENT 
RECORDS; AN EVALUATION OF THE ROLE OF DATA QUALITY 
239.Steinar Krokstad: SOCIOECONOMIC INEQUALITIES IN HEALTH AND DISABILITY. 
SOCIAL EPIDEMIOLOGY IN THE NORD-TRØNDELAG HEALTH STUDY (HUNT), 
NORWAY 
240.Arne Kristian Myhre: NORMAL VARIATION IN ANOGENITAL ANATOMY AND 
MICROBIOLOGY IN NON-ABUSED PRESCHOOL CHILDREN 
241.Ingunn Dybedal: NEGATIVE REGULATORS OF HEMATOPOIETEC STEM AND 
PROGENITOR CELLS 
242.Beate Sitter: TISSUE CHARACTERIZATION BY HIGH RESOLUTION MAGIC ANGLE 
SPINNING MR SPECTROSCOPY 
243.Per Arne Aas: MACROMOLECULAR MAINTENANCE IN HUMAN CELLS – REPAIR OF 
URACIL IN DNA AND METHYLATIONS IN DNA AND RNA 
244.Anna Bofin:  FINE NEEDLE ASPIRATION CYTOLOGY IN THE PRIMARY 
INVESTIGATION OF BREAST TUMOURS AND IN THE DETERMINATION OF 
TREATMENT STRATEGIES 
245.Jim Aage Nøttestad: DEINSTITUTIONALIZATION AND MENTAL HEALTH CHANGES 
AMONG PEOPLE WITH MENTAL RETARDATION 
246.Reidar Fossmark:  GASTRIC CANCER IN JAPANESE COTTON RATS 
247.Wibeke Nordhøy:  MANGANESE AND THE HEART, INTRACELLULAR MR RELAXATION 
AND WATER EXCHANGE ACROSS THE CARDIAC CELL MEMBRANE 
2005 
248.Sturla Molden:  QUANTITATIVE ANALYSES OF SINGLE UNITS RECORDED FROM THE 
HIPPOCAMPUS AND ENTORHINAL CORTEX OF BEHAVING RATS 
249.Wenche Brenne Drøyvold:  EPIDEMIOLOGICAL STUDIES ON WEIGHT CHANGE AND 
HEALTH IN A LARGE POPULATION.  THE NORD-TRØNDELAG HEALTH STUDY 
(HUNT) 
250.Ragnhild Støen:  ENDOTHELIUM-DEPENDENT VASODILATION IN THE FEMORAL 
ARTERY OF DEVELOPING PIGLETS 
251.Aslak Steinsbekk:  HOMEOPATHY IN THE PREVENTION OF UPPER RESPIRATORY 
TRACT INFECTIONS IN CHILDREN 
252.Hill-Aina Steffenach:  MEMORY IN HIPPOCAMPAL AND CORTICO-HIPPOCAMPAL 
CIRCUITS
253.Eystein Stordal:  ASPECTS OF THE EPIDEMIOLOGY OF DEPRESSIONS BASED ON SELF-
RATING IN A LARGE GENERAL HEALTH STUDY (THE HUNT-2 STUDY) 
254.Viggo Pettersen:  FROM MUSCLES TO SINGING:  THE ACTIVITY OF ACCESSORY 
BREATHING MUSCLES AND THORAX  MOVEMENT IN CLASSICAL SINGING 
255.Marianne Fyhn:  SPATIAL MAPS IN THE HIPPOCAMPUS AND ENTORHINAL CORTEX 
256.Robert Valderhaug:  OBSESSIVE-COMPULSIVE DISORDER AMONG CHILDREN AND 
ADOLESCENTS:  CHARACTERISTICS AND PSYCHOLOGICAL MANAGEMENT OF 
PATIENTS IN OUTPATIENT PSYCHIATRIC CLINICS 
257.Erik Skaaheim Haug:  INFRARENAL ABDOMINAL  AORTIC ANEURYSMS – 
COMORBIDITY AND RESULTS FOLLOWING OPEN SURGERY 
258.Daniel Kondziella: GLIAL-NEURONAL INTERACTIONS IN EXPERIMENTAL BRAIN 
DISORDERS 
259.Vegard Heimly Brun:  ROUTES TO SPATIAL MEMORY IN HIPPOCAMPAL PLACE CELLS 
260.Kenneth McMillan:  PHYSIOLOGICAL ASSESSMENT AND TRAINING OF ENDURANCE 
AND STRENGTH IN PROFESSIONAL YOUTH SOCCER PLAYERS 
261.Marit Sæbø Indredavik:  MENTAL HEALTH AND CEREBRAL MAGNETIC RESONANCE 
IMAGING IN ADOLESCENTS WITH LOW BIRTH WEIGHT 
262.Ole Johan Kemi:  ON THE CELLULAR BASIS OF AEROBIC FITNESS, INTENSITY-
DEPENDENCE AND TIME-COURSE OF CARDIOMYOCYTE AND ENDOTHELIAL 
ADAPTATIONS TO EXERCISE TRAINING 
263.Eszter Vanky: POLYCYSTIC OVARY SYNDROME – METFORMIN TREATMENT IN 
PREGNANCY 
264.Hild Fjærtoft:  EXTENDED STROKE UNIT SERVICE AND EARLY SUPPORTED 
DISCHARGE.  SHORT AND LONG-TERM EFFECTS   
265.Grete Dyb:  POSTTRAUMATIC STRESS REACTIONS IN CHILDREN AND ADOLESCENTS 
266.Vidar Fykse: SOMATOSTATIN AND THE STOMACH 
267.Kirsti Berg: OXIDATIVE STRESS AND THE ISCHEMIC HEART:  A STUDY IN PATIENTS 
UNDERGOING CORONARY REVASCULARIZATION  
268.Björn Inge Gustafsson:  THE SEROTONIN PRODUCING ENTEROCHROMAFFIN CELL, 
AND EFFECTS OF HYPERSEROTONINEMIA ON HEART AND BONE 
